Extracellular and Intracellular Regulation of G Protein-Coupled Receptor Signaling

Joseph E. Rittiner

A dissertation submitted to the faculty of the University of North Carolina at Chapel Hill in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the School of Pharmacy (Chemical Biology and Medicinal Chemistry)

Chapel Hill
2013

Approved by:

Alexander Tropsha

Mark J. Zylka

Stephen Frye

Ken McCarthy

T. Kendall Harden
ABSTRACT

Joseph E. Rittiner: Extracellular and Intracellular Regulation of G Protein-Coupled Receptor Signaling
(Under the direction of Dr. Mark J. Zylka)

Signaling through G protein-coupled receptors (GPCRs) is an essential part of cellular communication, and nearly half of modern pharmaceuticals target GPCRs in some way. GPCRs are also subject to extensive biological regulation, which is incompletely understood. Here, I examined both extracellular metabolic control of GPCR signaling, and intracellular feedback mechanisms which regulate downstream signal transduction and receptor desensitization. I first found that the nucleotide adenosine 5’-monophosphate (AMP) is an agonist of the A<sub>1</sub> adenosine receptor. Previously, AMP was thought to signal exclusively via hydrolysis to adenosine, and no AMP receptor was known to exist. Using a novel real-time assay of adenosine receptor activity, I showed that AMP directly activates A<sub>1</sub>R independent of hydrolysis to adenosine, but that activation of the adenosine A<sub>2B</sub> receptor required hydrolysis to adenosine. I also identified a histidine residue in the A<sub>1</sub>R binding pocket critical for receptor activation by AMP, but not adenosine. These results suggest that some of the A<sub>1</sub>R-mediated physiological effects attributed to adenosine may in fact be directly caused by AMP. Furthermore, I found that extracellular loop 2 partially determines A<sub>1</sub>R sensitivity to AMP, and that AMP stimulation elicits differential activation of signaling cascades downstream of A<sub>1</sub>R. In subsequent work, I found that the novel lipid kinase
diacylglycerol kinase eta (DGKη) positively modulates signaling downstream of muscarinic and purinergic GPCRs. This effect required DGKη catalytic activity, but only a minimal level of DGKη expression. DGKη expression also suppressed extracellular signal-related kinase (ERK) phosphorylation downstream of protein kinase C (PKC) and both activation and depletion of PKC abolished the DGKη effect on GPCR signaling, indicating that DGKη enhances GPCR signaling by suppressing PKC activation, likely reducing receptor desensitization. Enhanced expression of DGKη is linked to bipolar disorder (BPD), suggesting that increased DGKη activity contributes to the dysregulation of GPCR and PKC signaling in BPD and that DGKη inhibitors may have therapeutic potential for the treatment of BPD. Together, my work expands the current understanding of adenosine receptor signaling, implies an enhanced role for multiple endogenous ligands and functional selectivity in physiological GPCR signaling, and highlights GPCR-modulating enzymes as targets for drug discovery.
ACKNOWLEDGEMENTS

First of all, I would like to thank Mark, for providing me a temporary home, a sweet microscope, lots of advice, and infinite coffee. Thanks most of all for allowing me the freedom to explore my projects in my own way, and for help with my writing. Your patience has been appreciated. I would also like to thank the “prodrug meeting” (now with less prodrugs!) crew, Stephen, Jian, Bill, and Emily, for providing a sounding board for potential experiments and bringing invaluable real-world experience to the proceedings. And of course, thanks to Ilia for the samurai journey, you totally saved the day.

I would like to thank the members of the Zylka lab, past and present, for various opinions and advice, both scientific and extracurricular. It has been a strange treat to watch the lab triple in size since I’ve been here. Thanks for making the lab a wonderful environment to work in, because trust me, there are plenty of labs that aren’t. I would not have survived without the various lab managers through the ages: Yvette, Brendan, Sarah, and Gabby; thanks for keeping everything running. Thanks also to Vicki, for swooping in at the perfect time to take my second project off my hands, so that I could focus on graduating without worrying about it. But most of all, thanks to Julie, for showing me how to work hard and keep a sense of humor, and for teaching me what medicinal chemistry is all about.

Lastly, and most importantly, I would like to thank my family for all of the love and support over the years. I know it probably seemed like I would be in grad school until the end of days, but it’s over now, and I would have never made it without you. Mua!
# TABLE OF CONTENTS

List of Tables .................................................................................................................. vii
List of Figures .................................................................................................................. viii
List of Abbreviations ...................................................................................................... x

Chapter 1: A brief introduction to GPCR signaling ......................................................... 1

Chapter 2: The nucleotide AMP is an adenosine A1 receptor agonist
   Introduction .................................................................................................................. 11
   Materials and Methods ............................................................................................. 13
   Results ......................................................................................................................... 20
   Discussion .................................................................................................................. 52

Chapter 3: Further investigation of A1R signaling
   Introduction .................................................................................................................. 56
   Materials and Methods ............................................................................................. 59
   Results ......................................................................................................................... 61
   Discussion .................................................................................................................. 75

Chapter 4: Diacylglycerol kinase eta prolongs GPCR signaling by attenuating protein kinase C activation
   Introduction .................................................................................................................. 81
   Materials and Methods ............................................................................................. 83
   Results ......................................................................................................................... 92
   Discussion .................................................................................................................. 120

Chapter 5: Conclusions and future directions ............................................................... 124

References ..................................................................................................................... 133
LIST OF TABLES

Table 1. hA1R dose responses for Ca$^{2+}$ mobilization assay and Glosensor assay .................42
LIST OF FIGURES

Figure 1.1. Selected signaling pathways downstream of GPCR activation.............................4

Figure 2.1. Real-time visualization of adenosine receptor activation and
ectonucleotidase activity........................................................................................................21

Figure 2.2. AMP directly activates hA₁R whereas AMP activates hA₂B R
indirectly via ectonucleotidase-catalyzed hydrolysis to adenosine ......................................25

Figure 2.3. AMP activates mouse A₁R ..............................................................................27

Figure 2.4. A non-hydrolyzable AMP analog activates hA₁R but not hA₂B R .....................30

Figure 2.5. Adenosine, AMP and ACP stimulate calcium mobilization in COS7 cells .......32

Figure 2.6. Dose-response curves for adenosine, AMP and related analogs at hA₁R ..........36

Figure 2.7. Adenosine, AMP and related analogs inhibit cAMP
accumulation in hA₁R-expressing cells .............................................................................38

Figure 2.8. Adenosine, AMP and related analogs do not inhibit cAMP
accumulation in cells lacking hA₁R ..................................................................................40

Figure 2.9. ACP inhibits cAMP accumulation in mouse embryonic cortical neurons .......44

Figure 2.10. AMP activates hA₁R independent of P2Y receptor activity .........................48

Figure 2.11. Expression and activity of hA₁R point mutants .............................................50

Figure 3.1. Adenosine receptor sensitivity to AMP is partially determined
by extracellular loop 2 ........................................................................................................63

Figure 3.2. Adenosine and AMP have similar potencies but very different
efficacies when stimulating hA₁R activation of Gαq ......................................................67

Figure 3.3. Compounds 3a and 3d are full agonists of human A₁R in a
calcium mobilization assay ...............................................................................................70
Figure 3.4. Compound 3a does not have long-lasting effects on heart rate or body temperature while CPA causes a significant decrease in heart rate and body temperature in wild-type mice .................................................................73

Figure 4.1. Mouse DGKη is catalytically active and prolongs GPCR signaling ...............94

Figure 4.2. DGKη catalytic activity is required to prolong GPCR signaling ......................98

Figure 4.3. Expression of DGKη truncation constructs in HEK293 cells .........................101

Figure 4.4. Catalytic activity and signaling effects of DGKη truncation constructs ..........103

Figure 4.5. DGKη does not affect intracellular calcium stores ........................................107

Figure 4.6. DGKη does not translocate within cells after GPCR stimulation ....................111

Figure 4.7. DGKη prolongs GPCR signaling via PKC ..................................................113

Figure 4.8. DGKη reduces baseline and GPCR agonist-evoked phosphorylation of ERK ..116

Figure 4.9. Model showing how DGKη prolongs Gαq-coupled GPCR signaling ...........118
LIST OF ABBREVIATIONS

$A_1$R – adenosine $A_1$ receptor
$A_{2A}$R – adenosine $A_{2A}$ receptor
$A_{2B}$R – adenosine $A_{2B}$ receptor
$A_3$R – adenosine $A_3$ receptor
$\alpha\beta$-met-ADP – $\alpha,\beta$-methylen-ADP
ACP – deoxyadenosine 5’-monophosphonate
AC – adenylyl cyclase
AUC – area under the curve
BPD – bipolar disorder
cAMP – cyclic adenosine monophosphate
CCPA – 2-chloro-$N^6$-cyclopentyladenosine
CNS – central nervous system
CPA – $N^6$-cyclopentyladenosine
CPX – 8-cyclopentyl-1,3-dipropylxanthine
DAG – diacylglycerol
DGK – diacylglycerol kinase
DMT – N,N-dimethyltryptamine
EGFR – epidermal growth factor receptor
ERK – extracellular signal-related kinase
GDP – guanosine diphosphate
GPCR – G protein-coupled receptor
GRK – G protein-coupled receptor kinase
GTP – guanosine triphosphate
h – human
IP$_3$ – inositol 1,4,5-triphosphate
m – mouse
NT5E – ecto-5’-nucleotidase
PAP – prostatic acid phosphatase
PA – phosphatidic acid
PDE – phosphodiesterase
PIP$_2$ – phosphatidylinositol 4,5-bisphosphate
PKA – protein kinase A
PKC – protein kinase C
PLC – phospholipase C
PMA – phorbol-12-myristate-13-acetate
RGS – regulator of G protein signaling
SERCA – sarco/endoplasmic reticulum calcium ATPase
WT – wild-type
G protein-coupled receptors (GPCRs) are a fundamental part of cellular communication in all eukaryotic organisms. Indeed, the importance of GPCRs in biological signaling is difficult to overstate; they are responsible for an estimated 80% of all signal transduction across biological membranes (1). Furthermore, GPCRs are highly druggable proteins, and are an essential component of modern pharmacology. As of 2013, over 30% of the small-molecule drugs currently on the market target GPCRs in some fashion (2). As such, a thorough understanding of GPCR structure and function is crucial both in the investigation of biological signaling processes and in future drug discovery. As recognition of the importance of GPCR signaling, multiple researchers have received Nobel Prizes in Chemistry or Medicine for work on GPCR signaling, including Alfred Gilman and Martin Rodbell in 1994 for the discovery of G proteins, Richard Axel and Linda Buck in 2004 for the characterization of olfactory receptors, and Brian Kobilka and Robert Lefkowitz in 2012 for work examining the structure and signaling mechanisms of GPCRs.

GPCRs span the cellular plasma membrane, and a significant portion of a given GPCR exists within the interior of the lipid bilayer. As such, detailed information regarding GPCR structure was unavailable for many years, as their amphiphilic composition – which is stabilized by the lipid bilayer, but not stable in aqueous solution – makes GPCR crystallization extremely difficult. However, high resolution crystal structures of multiple GPCRs including rhodopsin (3-5), the β2 adrenergic receptor (6-8), and the A2A adenosine...
receptor (9-11) have now been solved, providing a more complete understanding of GPCR structure and function.

The core structural component of all GPCRs is a series of 7 transmembrane α-helices, arranged in a roughly cylindrical bundle. These helices are traditionally numbered I-VII, in order from N- to C-terminus. The N-terminus of GPCRs is always located on the extracellular side of the plasma membrane, and is often heavily N-glycosylated; this complex glycosylation is required for proper expression and trafficking of GPCRs (12). Conversely, the C-terminus is located on the intracellular face of the plasma membrane, and is important for interactions with scaffolding and regulatory proteins. The proximal portion of the C-terminus consists of another α-helix (helix VIII) oriented parallel to the plasma membrane and anchored by palmitoylation of one or more conserved cysteine residues (13,14).

The transmembrane helices are connected by three extracellular and three intracellular loops (EL1-EL3 and IL1-IL3, respectively). Of the extracellular loops, EL2 is of particular interest, as it is stabilized by a highly-conserved disulfide bond with the extracellular end of helix III (15), and is often located in close proximity to the ligand binding site (16). Of the intracellular loops, IL2 and IL3 are the most noteworthy, as they constitute a significant portion of the G protein coupling interface. Furthermore, IL2 is anchored by a very highly conserved E/DRY series of residues at the cytoplasmic end of helix III, which is believed to be involved in stabilizing receptor conformational states (17). In the vast majority of GPCRs, the ligand binding pocket is located between the extracellular ends of the transmembrane helices, within the plasma membrane. However, the members of a small subfamily, the class C GPCRs, have a large N-terminal ligand binding domain that extends into the extracellular space (18).
GPCRs signal primarily through interactions with heterotrimeric G proteins. As implied by the name, heterotrimeric G proteins are composed of three subunits, α (alpha), β (beta), and γ (gamma). The Gα subunits are homologous to the Ras family of small GTPase signaling proteins (19), and function in a similar fashion. However, unlike small GTPases, Gα subunits are tethered to the plasma membrane by N-terminal myristoylation and/or palmitoylation (20). In their inactive state, Gα subunits bind a molecule of guanosine diphosphate (GDP), and form a complex with Gβ, Gγ, and a coupled GPCR. Upon ligand binding, GPCRs undergo a conformational change which causes the release of GDP from the coupled Gα subunit, where it is replaced by a molecule of guanosine triphosphate (GTP) from the cytosol. The precise characteristics of this conformational change have only recently begun to be elucidated. As currently understood, agonist binding causes an outward motion in the cytoplasmic ends of transmembrane helices V and VI, creating a cavity into which the C-terminus of the coupled Gα subunit extends (8,21).

GTP binding causes a conformational change in Gα, which results in the dissociation of the Gα subunit from the coupled GPCR and the other G protein subunits. In their active, GTP-bound state, Gα subunits diffuse freely throughout the plasma membrane, where they interact with and activate various membrane-bound second messenger proteins (Fig. 1.1). G protein signaling is terminated by the enzymatic hydrolysis of Gα-bound GTP into GDP, which causes the Gα subunit to revert back to its inactive conformation and re-associate with the β and γ subunits of the heterotrimeric G protein complex (22). In isolation, Gα subunits catalyze GTP hydrolysis very poorly. However, signal termination is facilitated by a large family of regulator of G protein signaling (RGS) proteins, which greatly enhance the rate of GTP hydrolysis through interactions with active Gα subunits (23).
Figure 1.1

[Diagram of GPCR signaling pathway showing interactions between various proteins and molecules such as AC, PDE, cAMP, PKA, GRK, PKC, Ca\(^{2+}\), CaM, Raf, MEK, ERK, GIRK, and K\(^+\).]
Figure 1.1. Selected signaling pathways downstream of GPCR activation.

Numerous downstream signaling pathways can be activated after stimulation of a given GPCR, determined mainly by the type of Gα subunit coupled to the receptor (Fig. 1.1). The Gα subunits of heterotrimeric G proteins are grouped into 4 main families, Gs, Gi, Gq, and G12, based on sequence homology and signaling activity (24). Of these, the Gs and Gi families signal primarily by modulating intracellular levels of cyclic adenosine monophosphate (cAMP). The Gs (stimulatory) family contains two members: Gαs, which is ubiquitously expressed, and Gαolf, which is exclusively expressed in the olfactory system and is responsible for signal transduction through the large olfactory subfamily of GCPRs (25). Activation of Gs-family Gα subunits leads to stimulation of adenylyl cyclase (AC), which converts ATP into cAMP, raising intracellular concentrations of cAMP (Fig. 1.1). Elevated cyclic AMP leads to the activation of protein kinase A (PKA), which phosphorylates multiple downstream effectors.

The Gi (inhibitory) family contains 5 members: Gαi, Gαo, Gαz, Gαt (transducin), and Gαgust (gustducin). While the Gαi, Gαo, and Gαz subunits are widely expressed, transducin is exclusively expressed in the vision system, and couples to the light sensitive GPCRs rhodopsin and the three cone opsins (26). Similarly, gustducin is exclusively expressed in the taste and gastrointestinal systems (27,28). Activation of Gi-family Gα subunits leads to inhibition of adenylyl cyclase and the stimulation of phosphodiesterase (PDE) enzymes which hydrolyze cAMP (Fig. 1.1). Both of these activities decrease intracellular levels of cAMP, leading to a suppression of PKA activity and its associated downstream effectors. Activation of transducin more specifically results in the stimulation of a cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase, leading to the closing of cGMP-gated cation channels, a critical step in visual signal transduction (29).
The Gq family contains 5 members: Gαq, Gα11, Gα14, Gα15, and Gα16. The Gq family transduces signals using an entirely different second messenger system than the Gs and Gi families (Fig. 1.1). Activation of Gq-family Gα subunits leads to the stimulation of phospholipase C (PLC), which catalyses the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP_2) into inositol-1,4,5-triphosphate (IP_3) and diacylglycerol (DAG). IP_3 activates IP_3 receptors on the endoplasmic reticulum, leading to the release of intracellular calcium stores and an increase in cytosolic calcium concentration. DAG activates conventional and novel isoforms of protein kinase C (PKC), leading to the phosphorylation of multiple downstream effectors (30), including MAP kinase cascades which culminate in the phosphorylation and activation of extracellular signal-related kinase (ERK). Elevated calcium also activates multiple downstream effectors, including conventional isoforms of PKC (30) and calmodulin-regulated proteins (31).

The G12 family contains two members: Gα_{12} and Gα_{13}. The G12 family signals primarily via downstream activation of the Rho family of GTPases (32), and is poorly understood compared to the Gs, Gi, and Gq families. All GPCRs identified thus far that couple to the G12 family also couple to one of the other Gα families (32), suggesting that G12 may function in a secondary signaling role (G12 not shown in Fig. 1.1).

The GPCR-coupling selectivity of Gα subunits is primarily determined by the extreme C-terminal 5 amino acids (33,34), which extend into a cavity formed between the intracellular ends of the GPCR transmembrane helices upon receptor activation (8). However, the structural determinants of Gα-coupling selectivity of GPCRs are more complex, broadly encompassing the intracellular loops, intracellular regions of the transmembrane helices, and the proximal portion of the C-terminus. Most GPCRs
preferentially couple to a single Gα family, but many GPCRs can couple to multiple Gα families under certain circumstances. For example, Gα-coupling selectivity (and binding to other intracellular proteins) in a single activated GPCR can be directed by the structure of the activating agonist, a phenomenon known as functional selectivity (35). GPCR coupling selectivity can also be influenced by dimerization or oligomerization of the receptor (36).

The other two members of the heterotrimeric G protein complex, Gβ (beta) and Gγ (gamma), form an obligate dimer and as such are usually referred to together as the G beta-gamma complex, or simply Gβγ. There are currently 5 known isoforms of Gβ, and 11 known isoforms of Gγ (37), which can form numerous combination of Gβγ pairs with different signaling properties (38). Gβγ is tethered to the plasma membrane by farnesylation or geranylgeranylation of the C-terminus of Gγ (20), and binds the inactive, GDP-bound state of Gα subunits. Upon guanine nucleotide exchange, Gβγ is released from Gα; free Gβγ diffuses along the plasma membrane and activates downstream effectors independently of Gα. The signaling roles of free Gβγ are poorly understood, at least compared to the current understanding of Gα signaling. The most well-characterized activity of free Gβγ is gating the opening of G protein coupled inward rectifying potassium channels (GIRKs) (39). However, free Gβγ can also activate PLC (40,41), and phospholipase A2 (42), among other downstream effectors (Fig. 1.1).

After activation, GPCRs are phosphorylated by downstream effector kinases at multiple locations on the intracellular loops and C-terminus (Fig 1.1, red). GPCRs are directly phosphorylated by both PKA (43) and PKC (44), as well as by G protein-coupled receptor kinases (GRKs), which are themselves activated by Gβγ, PKA, and PKC (45,46). This feedback mechanism can have multiple effects on GPCR function, with the particular
fate of receptor signaling depending on the pattern of phosphorylation and the specific receptor (47). Among these regulatory effects, GPCR phosphorylation can directly and indirectly cause uncoupling of the GPCR from Ga subunits, leading to a termination of signaling downstream of GPCR activation (48), a process known as desensitization. In some cases, GPCR phosphorylation may also modify receptor ability to couple to different Ga subunits (49), effectively redirecting GPCR signaling to different downstream pathways (50), though this is somewhat controversial (51). Lastly, and perhaps most importantly, GPCR phosphorylation promotes the recruitment of β-arrestin proteins to activated GPCRs (Fig. 1.1, blue), which has multiple signaling functions.

β-arrestin binding to GPCRs occludes the interface required for Ga subunit coupling, leading to receptor uncoupling and desensitization (52). Additionally, β-arrestin acts as a scaffolding protein, recruiting proteins required for endocytosis, such as clathrin (53) and AP-2 (54), to the GPCR signaling complex. As such, β-arrestin is important in both short-term (receptor desensitization by disruption of G protein coupling) and long-term (receptor internalization through endocytosis) negative regulation of receptor activity. β-arrestins can also recruit enzymes which terminate second messenger signaling downstream of GPCR activation. For example, β-arrestins recruit PDEs (which hydrolyze the second messenger cAMP) downstream of Gaq signaling (55), and diacylglycerol kinases (which phosphorylate the second messenger DAG) downstream of Gαq signaling (56). Lastly, β-Arrestin recruitment actually stimulates other downstream signaling pathways, such as MAP kinase cascades leading to ERK phosphorylation (Fig. 1.1) (57).

In addition to β-arrestins, GPCRs interact with numerous other scaffolding and accessory proteins, including ion channels, 14-3-3 proteins, PDZ-domain proteins, A-kinase
anchoring proteins, and others (58). Apart from the regulation of GPCR signaling itself, these associations are important for receptor trafficking, localization, and cytoskeletal anchoring in lipid rafts and signaling complexes (58,59). As partially detailed in Figure 1.1, which presents only a very limited view, GPCRs can influence a staggering number of intracellular signaling pathways. The what, when, and where of these downstream signaling events, and thus their integration into biological signaling networks, is subject to very complex and detailed regulation, about which we understand very little. Indeed, given the tremendous importance of GPCRs in nearly every type of extracellular and intracellular signaling, the current scientific understanding of GPCR signaling and regulation is incomplete at best. As such, further efforts to characterize the endogenous regulation of GPCR signaling are of the utmost importance in developing a better understanding of the molecular bases of normal biological signaling. However, a better understanding of the role of GPCRs in abnormal biological signaling is even more critical, given the enormous potential – both past and future – of GPCRs as targets for therapeutic drug discovery.
CHAPTER 2: THE NUCLEOTIDE AMP IS AN ADENOSINE A1 RECEPTOR AGONIST

INTRODUCTION

Adenosine and adenine nucleotides regulate diverse physiological processes (60,61). Adenosine activates four distinct G protein-coupled receptors, the so called P1 purinergic receptors: adenosine A1 receptor (A1R, ADORA1), adenosine A2A receptor (A2AR, ADORA2A), adenosine A2B receptor (A2BR, ADORA2B), and adenosine A3 receptor (A3R, ADORA3). A1R and A3R are Gi/o-coupled and inhibit adenylate cyclase when activated while A2AR and A2BR are Gs-coupled and stimulate adenylate cyclase.

While mammals have numerous P2 purinergic receptors for ATP and ADP, no receptor for their hydrolysis product (AMP) has been definitively identified. GPR80/GPR99 was originally classified as an adenosine and AMP receptor (62), however this finding has now been discounted (63,64). AMP has diverse physiological effects, suggesting a receptor for AMP could exist (65-74).

Complicating studies with AMP is the fact that cells express multiple enzymes that hydrolyze extracellular AMP to adenosine, including ecto-5’-nucleotidase (NT5E, CD73), Prostatic acid phosphatase (PAP, ACPP) and several alkaline phosphatases (75-78). Genetic deletion or pharmacological inhibition of individual ectonucleotidases reduces, but does not always eliminate, the physiological effects of AMP (65,67,70,72,79). And, the most
commonly used ectonucleotidase inhibitor α,β-methylene-ADP (αβ-met-ADP) inhibits NT5E, but it does not inhibit PAP (70).

Many of the physiological effects of AMP are lost in A₁R knockout mice or can be blocked with adenosine receptor antagonists (65,67,70,72-74), suggesting adenosine is the active ligand. However, given the challenges associated with inhibiting all ectonucleotidases in complex tissues (79), direct activation of adenosine receptors by AMP cannot be so easily ruled out.

Extracellular AMP originates from multiple endogenous sources (75), and nucleotide release and hydrolysis can be rapid (79,80). Endogenous AMP could thus directly modulate diverse adenosine-receptor dependent processes, including cardiovascular disease, cancer, neurotransmission and gliotransmission (60,61,81-83).

To rigorously study direct and indirect effects of AMP on adenosine receptors, we developed a novel cell based assay utilizing chimeric G proteins to visualize human (h)A₁R and hA₂B R activation in real-time and at single cell resolution. We also used a non-hydrolyzable AMP analog to rule out the effects of AMP hydrolysis. Surprisingly, we found that AMP directly activated hA₁R, but not hA₂B R, and activation was independent of hydrolysis to adenosine. Our study thus indicates that A₁R is a receptor for the naturally occurring nucleotide AMP as well as a receptor for adenosine.
MATERIALS AND METHODS

Materials

Adenosine (A9251), AMP (01930), inosine (I4125), 2-chloro-N^6^-cyclopentyladenosine (C7938), N^6^-cyclopentyladenosine (C8031), α,β-methylene adenosine 5’-diphosphate (αβ-met-ADP; M3763), and pertussis toxin (P7208) were purchased from Sigma-Aldrich. Pyridoxalphosphate-6-azophenyl-2’,4’-disulfonic acid (PPADS; 0625) and suramin (1472) were purchased from Tocris Bioscience. Stock solutions of adenosine (10 mM), AMP (10 mM), αβ-met-ADP (50 µM), PPADS (10 mM), and suramin (10 mM) were made in Hank’s balanced salt solution assay buffer (HBSS, Gibco catalog #14025, supplemented with 9 mM HEPES, 11 mM D-glucose, 0.1% fatty-acid free bovine serum albumin, pH 7.3) and frozen at -80°C in single use aliquots. All other compounds were dissolved in HBSS assay buffer at final concentration immediately before use.

Molecular Biology

Full-length expression constructs for human A_1R (GenBank accession #AY136746) and human A_2BR (GenBank accession #AY136748) were obtained from the Missouri S&T Clone Collection (www.cdna.org). Human A_1R point mutants were generated by PCR-based mutagenesis. Chimeric G protein constructs (Gα_q,i5 and Gα_q,s5) and the mouse transmembrane (TM)-PAP (nt 64-1317 from GenBank accession # NM_207668) expression construct were previously described (76,84,85). Full-length expression constructs of mouse NT5E (nt 47-1777 from GenBank accession # NM_011851.3) and mouse A_1R (nt 1070-2053 from GenBank accession # NM_001008533) were generated by RT-PCR using C57BL/6
dorsal root ganglia cDNA as template. The TM-PAP and NT5E expression constructs hydrolyzed AMP when transfected into HEK293 cells (assessed using enzyme histochemistry; data not shown for NT5E and previously shown for TM-PAP [76]). PCR-generated constructs have a Kozak consensus sequence, were cloned into pcDNA3.1(+) and were sequence verified.

*Calcium Imaging*

HEK293 cells were grown on polylysine-coated glass bottom culture dishes (MatTek Corp, P35G-0-10-C) in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% Fetal Bovine Serum, 100 U/mL penicillin and 100 µg/mL streptomycin. Cells were transfected with Lipofectamine Plus (Invitrogen) in DMEM containing 1% Fetal Bovine Serum, which was replaced with fresh growth media after 4 hours. The total amount of DNA per transfection was adjusted to 1 µg by adding pcDNA 3.1(+). 100 ng of pCS-Venus was included in each transfection to identify transfected cells. Following transfection (~24 hours), cells were washed two times in Hank’s balanced salt solution assay buffer (HBSS, Gibco catalog #14025, supplemented with 9 mM HEPES, 11 mM D-glucose, 0.1% fatty-acid free bovine serum albumin, pH 7.3), then loaded for one hour at room temperature with 2 µM Fura-2 AM (Invitrogen, F-1221) and 0.02% Pluronic F-127 (Invitrogen, P3000-MP) in assay buffer. Cells were washed three times with assay buffer, incubated for 30 minutes at room temperature, and were imaged on a Nikon Eclipse Ti microscope.

A Sutter DG-4 light source (excitation 340 nm / 380 nm; emission 510 nm) and Andor Clara CCD camera were used to image calcium responses. Assay buffer was
refreshed immediately prior to imaging. Antagonists were added in assay buffer 3 minutes prior to imaging. Starting solution was aspirated and agonist solution added after 40 seconds of baseline imaging. We manually pipetted and aspirated solutions for all calcium imaging experiments. Only cells which expressed visible Venus protein, did not saturate the camera at a 40 ms exposure time, and had low (< 0.6) baseline Fura-2 ratios were analyzed. 500 ms excitation at 340 nm and 250 ms excitation at 380 nm were used for all experiments.

Calcium responses were analyzed in two ways. To create real-time response profiles, the Fura-2 fluorescence intensity ratio (340 nm/380 nm) at each time point was averaged over all transfected cells in each condition and then normalized relative to the average baseline fluorescence ratio before agonist addition. Calcium responses were also quantified by calculating the area under the curve (AUC) extending 1 minute from agonist addition, relative to the baseline fluorescence ratio, on a cell-by-cell basis. AUC values were then averaged over all cells in each condition. Calcium response profiles and AUC data are presented as mean ± s.e.m. To create dose response curves, GraphPad Prism was used to fit a variable slope dose response equation to the average AUC values for each agonist concentration.

**Cyclic AMP GloSensor Assay**

Cyclic AMP determinations were made using a modified GloSensor luciferase detection system (Promega). Low passage, subconfluent HEK293T cells (ATCC CRL-11268) grown in DMEM without phenol red (Gibco #31053) and supplemented with 10% Fetal Bovine Serum (Gibco #26140) were reverse transfected by spotting a calcium
phosphate DNA complex mixture containing 12.5 ng each of GloSensor 22F plasmid (Promega #E2301) and human A1R plasmid in 25 mM HEPES at pH 7.1, 140 mM sodium chloride, 0.75 mM disodium monophosphate and 250 mM calcium chloride. Cells were immediately added at a density of 20,000 cells per well using a Multidrop 384 (Titertek) to 384 well white, clear bottom tissue culture plates (Corning #3707). Cell plates were incubated for 24 hours at 37°C and 5% CO2. Sixteen point, 1:3 dilutions curves of test compounds starting at 100 µM final concentration were diluted to 4x final concentration in HBSS (Gibco #14175) supplemented with 2 mM HEPES, pH 7.5 and then added to the cell plates with a Multimek automated liquid handling device (Nanoscreen, Charleston, SC). Following a 10 minute incubation at room temperature, 50 µM 3-isobutyl-1-methylxanthine (Sigma) and 175 nM (-)-isoproterenol hydrochloride (Sigma) were added by Multimek. Seven minutes later, GloSensor cAMP reagent (Promega #E1291) containing 2% luciferin and supplemented with 0.2% NP40 (Tergitol, Sigma) to permeabilize the cells was added by Multimek along with a final 5 µL addition of 100% Ethanol (Decon Labs) to eliminate bubbles. Luminescence was read on an Envision plate reader (Perkin Elmer) for 15 minutes. Data from 95% of Vmax for isoproterenol (~10 minutes post GloSensor reagent addition) were normalized for scale to 100% response equivalent to the response of 1 µM 2-chloro-N6-cyclopentyladenosine and 0% response equal to the response from the isoproterenol alone.

_Cortical Neuron Dissociation and Culture_

Embryonic cortical neurons were cultured as previously described (86). Briefly, cortices from ~E16.5 embryos were dissected and digested in dissociation medium (DM) (98
mM Na$_2$SO$_4$, 30 mM K$_2$SO$_4$, 5.8 mM MgCl$_2$, 0.25 mM CaCl$_2$, 1 mM HEPES, 20 mM D-glucose, 0.125 mM NaOH, and 0.001% phenol red) containing 0.32 mg/mL L-cysteine (Sigma, W326305) and 20 U/mL papain (Roche, 10108014001) at 37°C for 20 minutes with occasional mixing. After digestion, cortices were washed twice with DM containing 1 mg/mL BSA (Sigma, A3912) and 1 mg/mL trypsin inhibitor (Sigma, T9128), followed by incubation in DM containing 10 mg/mL BSA and 10 mg/mL trypsin inhibitor for 2 minutes. Prepared cortices were then suspended in plating media (Neurobasal-A, Gibco, 10888) containing 4.5% FBS, 2% B27 (Gibco, 17504), 100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine) and gently disrupted by pipetting 15-20 times. The dissociated neurons were counted in a hemocytometer and plated at 1 x 10$^6$ cells/well in polylysine/laminin-coated 6-well plates containing plating media.

**Neuron Treatment and cAMP ELISA Assay**

After 1 day in vitro, neuron plating media was replaced with serum-free plating media (otherwise identical) for 1 hour. Afterwards, the media was replaced with Neurobasal-A containing 1 mM ACP or 1 µM N$^6$-cyclopentyladenosine (CPA) (Sigma, C8031) for 30 minutes. For untreated conditions, media was replaced with Neurobasal-A containing no additives. For antagonist conditions, 100 µM 8-cyclopentyl-1,3-dipropylxanthine (CPX) (Tocris, 0439) was added 15 minutes before agonist addition, and agonist solutions also contained 100 µM CPX. Following incubation, forskolin (Sigma, F6886) was added, to a final concentration of 10 µM. After a final 15 minute incubation, the media was aspirated, and the neurons were washed twice in ice-cold Dulbecco’s phosphate buffered saline (PBS)
(Sigma, D8537). Then, lysis buffer (provided with cAMP ELISA Kit) (R&D Systems, KGE002B) was added, and the neurons were scraped and collected.

The cAMP ELISA assay was performed according to manufacturer’s instructions. Briefly, cells were subjected to 2 freeze/thaw cycles from -20°C to room temperature to ensure cell lysis. Cells were then centrifuged at 600 x g for 10 minutes and the supernatant was isolated. Neuron samples and cAMP standards were added to a microplate containing immobilized cAMP antibody, followed by a labeled cAMP conjugate. After incubation and washes, a substrate solution was added, causing a colorimetric reaction proportional to the quantity of bound cAMP conjugate. After incubation, stop solution was added, and absorbance was measured on a BioTek Synergy HT plate reader. Standard curve fitting and sample analysis was performed using GraphPad Prism.

Immunohistochemistry

HEK293 cells were grown on poly-D-lysine (Sigma, P0899)-coated coverslips and transfected using Lipofectamine Plus with 1 µg (per coverslip) of wild-type or mutant hA1R. 24 hours after transfection, the cells were washed twice with PBS and fixed for 15 minutes with 4% paraformaldehyde in PBS. The cells were then washed 3 times with PBS for 5 minutes and permeabilized with 0.05% Triton-X-100 (Fisher, BP151) in PBS for 20 minutes. The cells were washed three times (5 minutes/wash) and blocked with 5% normal goat serum (NGS) in PBS for 30 minutes. Cells were then incubated with a 1:250 dilution of rabbit anti-hA1R primary antibody (Santa Cruz Biotechnology, sc-28995) in 10% NGS for 2 hours, and washed three times (10 minutes/wash) with 10% NGS. The cells were then incubated in the
dark for 1 hour with a 1:1000 dilution of Alexa 546-conjugated Goat anti-rabbit secondary antibody (Invitrogen, A11010) in 10% NGS. Cells were washed three times with PBS and mounted on glass slides. The following day, the slides were imaged on an Olympus FV1000 confocal microscope. Dissociated cortical neurons were immunostained for mA1R in the same way, except that incubation with primary antibody was conducted at 4°C overnight.
RESULTS

Chimeric G proteins can be used to visualize adenosine receptor activation in real time

 Activation of G\textsubscript{i}-coupled A\textsubscript{1}R or G\textsubscript{s}-coupled A\textsubscript{2B}R is typically quantified by measuring ligand-evoked decreases or increases in intracellular cAMP, respectively. However, these assays entail lysing cells at different times post-stimulation, hence these assays have limited temporal resolution and no cellular resolution. In an effort to develop a real-time readout of adenosine receptor activation, we co-transfected HEK293 cells with vectors encoding hA\textsubscript{1}R and G\textsubscript{q,i}-5 (Gqi), a chimeric G protein that couples G\textsubscript{i}-coupled receptors to phospholipase C (PLC) activation and calcium mobilization (Fig. 2.1) (85). In parallel, we co-transfected HEK293 cells with vectors encoding hA\textsubscript{2B}R and chimeric G\textsubscript{q,s}-5 (Gqs), to couple hA\textsubscript{2B}R to PLC and calcium mobilization (Fig. 2.1) (84). As controls, we found that adenosine (1 mM) did not evoke calcium mobilization in untransfected HEK293 cells or in cells expressing hA\textsubscript{1}R alone, hA\textsubscript{2B}R alone, Gqi alone or Gqs alone. However, a saturating concentration of adenosine (1 mM) evoked rapid onset calcium responses that slowly decayed in cells co-expressing hA\textsubscript{1}R + Gqi or hA\textsubscript{2B}R + Gqs (Fig. 2.2 A,B), indicating adenosine receptor activation can be monitored in real-time at cellular resolution.
Figure 2.1

![Diagram of AMP and A1R to A2BR pathways involving PAP, NT5E, Gqi, PLC, Gqs, and Ca2+](image-url)
Figure 2.1. Real-time visualization of adenosine receptor activation and ectonucleotidase activity.

G_i-coupled A_1R and G_s-coupled A_2B R do not mobilize intracellular calcium when activated in most cell types, including HEK293 cells. However, when A_1R or A_2B R are co-expressed with chimeric G proteins that couple to phospholipase C (PLC; G_q1, G_q2, respectively), receptor stimulation can be visualized in real-time using the calcium-sensitive dye Fura-2. PAP and NT5E hydrolyze extracellular AMP to adenosine. Real-time visualization allowed us to show that (1) AMP directly activates A_1R whereas (2) AMP activates A_2B R indirectly via ectonucleotidase-catalyzed hydrolysis to adenosine.
AMP activates hA1R independent of ectonucleotidases whereas hA2BR activation is ectonucleotidase-dependent

Since no AMP receptors have been definitively identified, we next hypothesized that AMP would only mobilize calcium in adenosine receptor-expressing cells after hydrolysis to adenosine by PAP or NT5E ectonucleotidases (Fig. 2.1). To test this hypothesis, we co-transfected cells with hA1R + Gqi vectors along with the membrane-bound ectonucleotidases PAP or NT5E. These ectonucleotidases were enzymatically active when expressed in HEK293 cells (see Materials and Methods). To our initial surprise, 1 mM AMP evoked calcium responses in hA1R + Gqi-expressing cells that were indistinguishable in onset and magnitude from calcium responses evoked by 1 mM adenosine, and co-expression of PAP or NT5E did not modify AMP-evoked responses (Fig. 2.2A). Similar results were observed in cells co-expressing mouse A1R + Gqi (Fig. 2.3). These AMP-evoked calcium responses were dependent on overexpressed A1R as AMP had no effect in HEK293 cells when Gqi was expressed alone (Fig. 2.2A, Fig. 2.3). Rapid activation of A1R was not due to contaminating levels of adenosine (adenosine was undetectable in our AMP stock solution based on high performance liquid chromatography analysis). Instead, our data suggested that a nucleotide (AMP) could directly activate the adenosine A1 receptor.

In contrast, adenosine (Fig. 2.2B, grey) and AMP (Fig. 2.2B, blue) evoked kinetically distinct calcium responses in hA2BR + Gqs co-expressing HEK293 cells. Specifically, adenosine evoked a rapid onset calcium response that peaked shortly after agonist addition, while AMP elicited a gradual calcium response that began approximately 15 seconds after agonist addition. Co-expression of PAP or NT5E significantly augmented the speed and magnitude of the AMP response (Fig. 2.2B, green, purple), suggesting these enzymes
accelerated hydrolysis of AMP to adenosine. Although HEK293 cells endogenously express hA2bR (62,87), AMP did not evoke calcium responses in cells expressing Gqs alone (Fig. 2.2B, black). Taken together, these data suggest that AMP only activates hA2bR indirectly following hydrolysis to adenosine.

To directly test if AMP activates hA1R or hA2bR as a result of ectonucleotidase activity, we repeated our experiments in the presence of α,β-methylene-ADP (αβ-met-ADP), a high-potency (Ki = 5 nM) NT5E inhibitor (88). We found that αβ-met-ADP did not inhibit adenosine- or AMP-evoked calcium responses in cells co-expressing hA1R + Gqi (with or without overexpressed ectonucleotidases) (Compare Fig. 2.2A to Fig. 2.2C), further suggesting that AMP stimulates hA1R directly. In contrast, 10 μM αβ-met-ADP completely inhibited the calcium response caused by AMP in hA2bR + Gqs-expressing cells (Fig. 2.2D, blue) but did not inhibit the adenosine-evoked calcium response (Fig. 2.2D, grey). αβ-met-ADP also significantly reduced the calcium response caused by AMP in NT5E co-expressing cells (Fig. 2.2D, purple) and marginally inhibited the calcium response caused by AMP in PAP co-expressing cells (Fig. 2.2D, green).
Figure 2.2
Figure 2.2. AMP directly activates hA₁R whereas AMP activates hA₂B R indirectly via ectonucleotidase-catalyzed hydrolysis to adenosine.

Calcium mobilization responses in HEK293 cells expressing (A, C) Gqi ± hA₁R or (B, D) Gqs ± hA₂B R. (C, D) Cells were incubated with the competitive NT5E inhibitor αβ-met-ADP (10 µM) for 3 minutes and then were stimulated with 1 mM agonist in the presence of 10 µM αβ-met-ADP. (Black) 1 mM AMP in the absence of a transfected adenosine receptor, but in the presence of the respective chimeric G protein. Area under curve (AUC) measurements extended for 1 minute from agonist addition. Paired t tests were used to compare AUC data. Black asterisks, statistically significant difference compared to adenosine stimulation. Blue asterisks, statistically significant difference compared to AMP stimulation (in receptor-expressing cells). *, p < 0.05; **, p < 0.005; ***, p < 0.0005. All data are the average of two experiments performed in duplicate. n = 20-74 cells per condition. All data, including calcium traces, are presented as means ± standard error.
Figure 2.3. AMP activates mouse A₁R.

Calcium mobilization responses in HEK293 cells expressing Gqi ± mA₁R. Agonists: (Grey) 1 mM adenosine. (Blue) 1 mM AMP. (Green) 1 mM AMP in PAP co-expressing cells. (Purple) 1 mM AMP in NT5E co-expressing cells. (Black) 1 mM AMP in the absence of a transfected adenosine receptor, but in the presence of Gqi. Area under curve (AUC) measurements extended for 1 minute from agonist addition. Paired t tests were used to compare AUC data. Black asterisks, significant difference compared to adenosine stimulation. Blue asterisks, significant difference compared to AMP stimulation (in A₁R-expressing cells). ***, p < 0.0005. All data are the average of three experiments. n = 18-34 cells per condition. All data, including calcium traces, are presented as means ± standard error.
A non-hydrolyzable AMP analog activates hA₁R but not hA₂B

We next sought to determine if 5’-deoxyadenosine monophosphonate (ACP), a non-hydrolyzable analog of AMP (88), could also activate hA₁R (Fig. 2.4 A,B). We found that 1 mM ACP evoked a rapid onset calcium response in hA₁R + Gqi-expressing cells (Fig. 2.4C, solid line) but no response in hA₂B + Gqs-expressing cells (Fig. 2.4C, dashed line). ACP, AMP and adenosine also evoked rapid calcium responses in COS7 cells expressing hA₁R + Gqi, but not Gqi alone, indicating that all of these compounds activate hA₁R when expressed in a different cell line (Fig. 2.5).
Figure 2.4

A

\[
\text{AMP}
\]

\[
\text{NH}_2
\]

\[
\text{O} \quad \text{P} \quad \text{O} \quad \text{O} \quad \text{H} \quad \text{H}
\]

B

\[
\text{ACP}
\]

\[
\text{NH}_2
\]

\[
\text{O} \quad \text{P} \quad \text{O} \quad \text{H} \quad \text{OH} \quad \text{OH}
\]

C

1 mM ACP

Intracellular Ca\(^{2+}\)

\(\Delta (F340/F380)\)

Time (s)

Area Under Curve (F340/F380) \(\times s\)

hA\(_1\)R

hA\(_2\beta\)R

***
Figure 2.4. A non-hydrolyzable AMP analog activates hA₁R but not hA₂B R.

A and B) Structures of (A) AMP and (B) the non-hydrolyzable analog ACP at physiological pH. C) Calcium mobilization responses elicited by 1 mM ACP in HEK293 cells expressing (solid line) hA₁R + Gqi or (dashed line) hA₂B R + Gqs. Cells expressing Gqi alone did not respond to ACP. AUC measurements extended for 1 minute from agonist addition. Paired t tests were used to compare AUC data. ***, p < 0.0005. Data are the average of one (hA₂B R) or two (hA₁R) experiments performed in duplicate. n = 28-73 cells per condition. All data, including calcium traces, are presented as means ± standard error.
Figure 2.5

[Bar graph showing the area under the curve for Fura 2 fluorescence (F340/F380) x s for Adenosine, AMP, and ACP with hA1R + Gqi and Gqi conditions.]

- Adenosine: Significantly different (***).
- AMP: Significantly different (***).
- ACP: Significantly different (***).
Figure 2.5. Adenosine, AMP and ACP stimulate calcium mobilization in COS7 cells.

Calcium mobilization in COS7 cells expressing (black) hA1R + Gqi or (grey) Gqi alone, and stimulated with the indicated compounds (at 1 mM). AUC measurements extended for 1 minute from agonist addition. Paired t tests were used to compare AUC data in the presence and absence of transfected hA1R. **, p < 0.005; ***, p < 0.0005. All experiments performed in duplicate. n = 15-21 cells per condition. All data are presented as means ± standard error.
Adenosine and AMP are equipotent hA₁R agonists

Since our experiments above were performed using a single concentration of agonist, we next performed dose-response experiments to determine agonist potency in hA₁R + Gqi-expressing cells (Fig. 2.6). We found that adenosine stimulated calcium responses with an EC₅₀ of 1.41 µM (Table 1), a value consistent with previously published measurements (71,89). Interestingly, the EC₅₀ and Eₘₐₓ of AMP in the absence or presence of αβ-met-ADP (to ensure AMP was not hydrolyzed by endogenous NT5E) were not significantly different from those of adenosine (Fig. 2.6, Table 1). The non-hydrolyzable analog ACP had an EC₅₀ of 26.1 µM, 15 fold higher than AMP. This reduced potency relative to AMP could reflect the charge difference between the phosphonate and phosphate groups (monoanionic verses dianionic at neutral pH, respectively, Fig. 2.4). The adenosine deamination product inosine had an EC₅₀ of 38.1 µM, 27 fold higher than adenosine. The high potency A₁R agonist 2-chloro-N⁶-cyclopentyladenosine (CCPA) evoked calcium responses with an EC₅₀ of 3.32 nM. The Hill slopes of all dose responses were near 1.

To test the potency of these compounds in an assay that does not depend on the use of chimeric G proteins, we utilized a modified Promega GloSensor assay (Fig. 2.7, see Materials and Methods for assay details). This assay measures agonist effects on isoproterenol-evoked cAMP accumulation using a luminescent reporter construct, and is conducted in cells containing only endogenous G proteins. When stimulating hA₁R-expressing cells with adenosine, we observed a bimodal dose response, with adenosine inhibiting cAMP accumulation at low concentrations and stimulating cAMP accumulation at high concentrations (Fig. 2.7B). The latter response was likely due to activation of Gₛ-coupled A₂ receptors, which HEK293 cells endogenously express (62,87). Indeed, adenosine
stimulated additional cAMP accumulation in cells transfected with empty vector (Fig. 2.8B). This bimodal response prevented us from obtaining an EC\textsubscript{50} value for adenosine.

In contrast, CCPA, AMP, ACP, and inosine exclusively inhibited cAMP accumulation in hA\textsubscript{1}R-expressing cells (Fig. 2.7 A, C-F) but had no effects in cells transfected with empty vector (Fig. 2.8 A, C-E). Incubation with 100 ng/ml pertussis toxin for 16 hr post-transfection abolished the A\textsubscript{1}R-mediated inhibition of cAMP accumulation by adenosine, AMP, and CCPA (data not shown), confirming that signaling was mediated through endogenous G\textsubscript{i} proteins. The rank order of agonist potency was similar between cAMP accumulation assays and calcium mobilization assays (Table 1). The EC\textsubscript{50} values of AMP were not significantly different in the presence or absence of 10 µM αβ-met-ADP (Fig. 2.7 C,D), further indicating AMP stimulates hA\textsubscript{1}R/G\textsubscript{i}-coupled signaling directly and independent of hydrolysis to adenosine. Moreover, AMP did not produce a bimodal response like adenosine, arguing that the signaling effects of AMP were specific to hA\textsubscript{1}R and not due to hydrolysis to adenosine.
Figure 2.6

![Graph showing the area under the curve for different agonists.](image)

Fura 2 - Area Under Curve (F340/F380) x s

- CCPA
- Adenosine
- AMP
- AMP + αβ-met-ADP
- ACP
- Inosine

log [Agonist], M
Figure 2.6. Dose-response curves for adenosine, AMP and related analogs at hA₁R.

Calcium mobilization in HEK293 cells expressing hA₁R + Gqi and stimulated with the indicated compounds. For AMP + αβ-met-ADP condition, cells were incubated with 10 μM αβ-met-ADP for 3 minutes and then were stimulated with AMP in the presence of 10 μM αβ-met-ADP. AUC measurements extended for 1 minute from agonist addition. All experiments performed in duplicate. n = 19-45 cells per condition. All data are presented as means ± standard error.
Figure 2.7

Graphs showing the effect of various compounds on cAMP accumulation.

A. CCPA

B. Adenosine

C. AMP

D. AMP + αβ-met-ADP

E. ACP

F. Inosine
Figure 2.7. Adenosine, AMP and related analogs inhibit cAMP accumulation in hA₁R-expressing cells.

HEK293T cells were co-transfected with a vector encoding hA₁R and GloSensor 22F plasmid then stimulated with (A) CCPA, (B) adenosine, (C) AMP, (D) AMP in the presence of 10 µM αβ-met-ADP, (E) ACP, or (F) inosine. Cells were incubated with test compound for 10 minutes, then 175 nM (-)-isoproterenol was added for 7 minutes to stimulate cAMP accumulation. Following incubation, GloSensor cAMP reagent was added and luminescence was measured. Data were normalized such that 100% inhibition is equal to the response at the maximal concentration of CCPA and 0% is equal to the response from isoproterenol alone. All experiments were performed in duplicate. All data are presented as means ± standard deviation.
Figure 2.8

(A) CCPA

(B) Adenosine

(C) AMP

(D) ACP

(E) Inosine
Figure 2.8. Adenosine, AMP and related analogs do not inhibit cAMP accumulation in cells lacking hA1R.

HEK293T cells were co-transfected with empty expression vector and GloSensor 22F plasmid then were stimulated with (A) CCPA, (B) adenosine, (C) AMP, (D) ACP, and (E) inosine. Cells were incubated with test compound for 10 minutes, then 175 nM (-)-isoproterenol was added for 7 minutes to stimulate cAMP accumulation. Following incubation, GloSensor cAMP reagent was added and luminescence was measured. All data were normalized such that 0% is equal to the response from isoproterenol alone. All experiments performed in duplicate. All data are presented as means ± standard deviation.
Table 1

hA₁R dose responses for Ca²⁺ mobilization assay and Glosensor assay

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Ca²⁺ mobilization EC₅₀ (µM)</th>
<th>Eₘₐₓ (%)</th>
<th>Inhibition of cAMP accumulation EC₅₀ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CCPA</td>
<td>0.00332</td>
<td>104.3 ± 2.0</td>
<td>0.0171</td>
</tr>
<tr>
<td>Adenosine</td>
<td>1.41</td>
<td>100</td>
<td>--</td>
</tr>
<tr>
<td>AMP</td>
<td>1.69</td>
<td>94.1 ± 14.1</td>
<td>0.816</td>
</tr>
<tr>
<td>AMP#</td>
<td>1.11</td>
<td>99.6 ± 3.3</td>
<td>0.601</td>
</tr>
<tr>
<td>ACP</td>
<td>26.1</td>
<td>69.4 ± 3.2</td>
<td>4.95</td>
</tr>
<tr>
<td>Inosine</td>
<td>38.1</td>
<td>97.2 ± 3.6</td>
<td>3.22</td>
</tr>
</tbody>
</table>

* Relative to adenosine; # In presence of 10 µM αβ-met-ADP
ACP inhibits forskolin-evoked cAMP accumulation in embryonic mouse cortical neurons

Since the experiments above relied upon overexpression of adenosine receptors, to further assess physiological relevance, we next sought to determine if the non-hydrolyzable AMP analog (ACP) could activate native A1R and native downstream signaling components in a primary cell type. We selected mouse embryonic cortical neurons because AMP directly activates mA1R (Fig. 2.3), mA1R is highly expressed (Fig. 2.9A) and A1R activation regulates the physiology of cortical neurons (83). We utilized a cAMP ELISA assay to measure the second messenger that is downstream of Gi-coupled mA1R. In addition, we used ACP to ensure that no adenosine was produced from endogenously expressed ectonucleotidases.

Stimulation of cortical neurons with the adenylyl cyclase activator forskolin (10 µM) for 15 minutes increased intracellular cAMP concentration by 10-fold compared to baseline (Fig. 2.9B, blue). The concentration of cAMP in neurons treated with 1 mM ACP for 30 minutes prior to forskolin stimulation was decreased 34.9% compared to neurons treated with forskolin alone (Fig 2.9B, green), and cAMP concentration decreased 57.2% in neurons treated with 1 µM N6-cyclopentyladenosine (CPA; Fig 2.9B, purple), a high potency A1R agonist. In addition, the potent A1R antagonist CPX (100 µM) completely blocked the effects of ACP and CPA, as evidenced by no decrease in cAMP concentration compared to forskolin alone (Fig 2.9C). Thus, these data indicate that a nonhydrolyzable AMP analog can directly activate endogenous signaling pathways downstream of endogenously expressed A1R (i.e. in cells that were not subjected to any genetic manipulation).
Figure 2.9

A

B

C

[|cAMP| (pmol/μg protein)

- Untreated
- Forskolin
- Forskolin + 1 mM ACP
- Forskolin + 1 μM CPA

+ 100 μM CPX
Figure 2.9. ACP inhibits cAMP accumulation in mouse embryonic cortical neurons.

Embryonic cortical neurons were dissociated and plated at approximately embryonic day 16.5. A) Confocal image of cortical neurons immunostained with an anti-A1R antibody. Scale bar = 10 µm. B and C) After 1 day in vitro, neurons were incubated for 30 minutes with 1 mM ACP or 1 µM CPA in the (B) absence or (C) presence of 100 µM CPX. Neurons were then stimulated with 10 µM forskolin for 15 minutes, washed, and lysed. Cell lysates were then applied to a cAMP ELISA assay according to manufacturer’s instructions. cAMP concentrations were normalized to total protein using a BCA protein assay. Blue asterisks, statistically significant difference compared to forskolin stimulation alone. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. Data are the average of four (- CPX) or two (+ CPX) experiments performed in duplicate. All data are presented as means ± standard error.
AMP stimulates hA₁R independent of P2Y receptors

HEK293/T cells express multiple P2Y receptors (64,90) and P2Y receptors can heterodimerize with A₁R, imparting a P2Y-like pharmacology on A₁R (91-93). In addition, P2Y receptors can be stimulated by AMP analogs but not by AMP (94). Thus, we evaluated whether AMP-evoked calcium responses in hA₁R-expressing cells could be blocked with non-selective P2Y antagonists (PPADS or suramin). We found that stimulation of untransfected HEK293 cells with 10 µM ATP elicited a rapid calcium response (Fig. 2.10A, grey). This response was blocked completely by 100 µM PPADS (Fig. 2.10A, blue) and by 100 µM suramin (Fig. 2.10A, green). However, the same concentrations of PPADS or suramin did not block calcium responses in hA₁R + Gqi-expressing cells that were stimulated with 10 µM adenosine (Fig. 2.10B) or 10 µM AMP (Fig. 2.10C). These data thus indicate that AMP signals directly through hA₁R, independent of P2Y receptor activity.

His251 and His278 in the ligand binding pocket are required for AMP to directly activate hA₁R

The crystal structures of an adenosine receptor (hA₂A) co-crystallized with adenosine and an adenosine analog were recently reported (10,11). From these structural views of the ligand binding pocket, we selected two positively charged histidine residues (H251 and H278; conserved in hA₁R) as possibly important for interacting with the negatively charged phosphate of AMP. We then mutagenized each of these histidine residues to a nonpolar residue (alanine), to generate hA₁R-H251A and hA₁R-H278A. We
confirmed that each mutant receptor was expressed and membrane-localized to the same extent as wild-type hA₁R (Fig. 2.11 A-C).

Next, we measured adenosine and AMP potency at the mutant receptors with our calcium mobilization assay (Fig. 2.11D). We performed these experiments in the presence of 10 µM αβ-met-ADP to prevent AMP from slowly being hydrolyzed to adenosine. In cells expressing hA₁R-H251A + Gqi, adenosine stimulated calcium mobilization with an EC₅₀ of 1.80 µM, essentially identical to what we observed when stimulating wild-type hA₁R with adenosine (Table 1). Likewise, mutation of H251 did not affect binding of a radiolabeled agonist to bovine A₁R (95). In contrast, the potency of AMP in hA₁R-H251A + Gqi-expressing cells was drastically reduced, so much so that we could not obtain a complete dose response. In cells expressing hA₁R-H278A + Gqi, we observed a very weak response after stimulation with 1 mM adenosine, but no response at lower concentrations. Furthermore, stimulation with 1 mM AMP elicited no response. This is also consistent with a previous report, which showed that mutation of H278 abolished agonist binding (95).

Taken together, our results provide compelling evidence that adenosine and AMP activate hA₁R directly, with activation requiring an agonist binding pocket residue (H278) that is conserved in all adenosine receptors. Furthermore, the positively charged H251 residue is critical for activation of hA₁R by a negatively charged nucleotide (AMP) but not by adenosine. Importantly, these mutagenesis experiments conclusively rule out the possibility that adenosine and AMP stimulate calcium mobilization through any other receptor in HEK293 cells.
Figure 2.10

A. 10 μM ATP

B. 10 μM Ado

C. 10 μM AMP
**Figure 2.10. AMP activates hA1R independent of P2Y receptor activity.**

A) Calcium mobilization responses in untransfected HEK293 cells stimulated with 10 µM ATP in the absence or presence of P2Y receptor antagonists (PPADS or suramin). B and C) Calcium mobilization responses in HEK293 cells expressing hA1R + Gqi following stimulation with (B) 10 µM adenosine or (C) 10 µM AMP, in the absence or presence of 100 µM PPADS or 100 µM suramin. Cells were incubated in 100 µM PPADS/suramin for 3 minutes prior to experiments. AUC measurements extended for 1 minute from agonist addition. Paired t tests were used to compare AUC data relative to agonist alone. ***, p < 0.0005. All data are the average of (A) one or (B, C) two experiments performed in duplicate. n = 21-74 cells per condition. All data, including calcium traces, are presented as means ± standard error.
Figure 2.11
Figure 2.11. Expression and activity of hA1R point mutants.

A – C) Confocal images of HEK293 cells expressing (A) wild-type hA1R, (B) hA1R-H251A or (C) hA1R-H278A and immunostained with anti-A1R antibodies. Untransfected HEK293 cells in the same field of view were not immunostained, confirming antibody specificity. Scale bar = 10 µm. D) Calcium mobilization in HEK293 cells co-expressing indicated hA1R mutant and Gqi then stimulated with increasing concentrations of the indicated compounds. For all conditions, cells were incubated with 10 µM αβ-met-ADP for 3 minutes and then were stimulated with agonist in the presence of 10 µM αβ-met-ADP. AUC measurements extended for 1 minute from agonist addition. All experiments performed in duplicate, except H278A – AMP, which was performed in triplicate. n = 17-49 cells per condition. All data are presented as means ± standard error.
DISCUSSION

Prior to our study, it was unknown if a receptor for AMP existed. An older study suggested AMP might act directly and indirectly on adenosine receptors (73); however, the investigators did not fully inhibit the multiple ectonucleotidases that are now known to hydrolyze AMP to adenosine (75,77,78). In addition, AMP has never been evaluated as an agonist with cloned adenosine receptors, possibly because all previous assays of adenosine receptor activation required relatively long incubation periods with agonist, causing uncertainty as to whether AMP or its hydrolysis product (adenosine) was the active compound.

Using a novel cell-based assay that allowed for real-time visualization of adenosine receptor activation, we found that AMP directly activated hA₁R, independent of hydrolysis. In support of this conclusion, we found that AMP activated hA₁R in HEK293 cells as effectively as adenosine, even after inhibition of the main ectonucleotidase in HEK293 cells. Furthermore, a non-hydrolyzable analog of AMP also activated hA₁R in heterologous cells and in primary neurons, demonstrating that activation was not due to hydrolysis to adenosine. Our data thus provide the first direct evidence that hA₁R is a receptor for the naturally occurring nucleotide AMP, and argue for reclassification of A₁R as an adenosine and nucleotide (AMP) receptor.

Inbe and colleagues previously reported that GPR80/GPR99 was a receptor for adenosine and AMP, although others could not reproduce this result (62-64). As suggested by Abbracchio and colleagues, GPR80/GPR99 may have been misidentified as a purinergic receptor because HEK293 cells (the cells used in the GPR80/GPR99 study and our present study) endogenously express P2Y receptors in addition to A2A R and A2B R. Alternatively,
heteromeric interactions between GPR80/GPR99 and endogenous purinergic receptors could hypothetically impart GPR80/GPR99 with a novel pharmacological profile.

Neither of these hypothetical possibilities explains why AMP activated hA1R in our assays. The HEK293 cells we used do contain A2 receptors (as evidenced by stimulation of cAMP production in cells transfected only with GloSensor plasmid, Fig. 2.8B) and P2Y receptors (as evidenced by ATP-evoked, P2Y antagonist-sensitive calcium responses, Fig. 2.10A). However, our data with P2Y antagonists rule out the possibility that AMP signaled through P2Y receptors. In addition, point mutations in hA1R shifted or eliminated responses to AMP, providing strong evidence that AMP signaled directly through hA1R and not through any other receptor in HEK293 cells. AMP also directly stimulated hA1R when expressed in a different mammalian cell line (COS7 cells; Fig. 2.5).

Our findings were also not an artifact of using a chimeric G protein to couple hA1R to calcium mobilization. Indeed, we found that AMP (±αβ-met-ADP) and ACP activated hA1R when coupled to endogenous Gi proteins using the GloSensor cAMP accumulation assay and that this effect could be blocked by Gi-specific disruption with pertussis toxin. Our findings were not an artifact of overexpressing A1R, as ACP inhibited forskolin-induced cAMP accumulation in mouse cortical neurons that contain only native A1R and downstream signaling components.

There is a large amount of structure-activity data with 5’-substituted adenosine analogs, all of which indicate that A1R is tolerant of bulky and negatively charged groups at the 5’-position (96-98). This includes 5’-ester, 5’-carbamoyl, 5’-halogen and 5’-sulfide derivatives of adenosine analogs, many of which are low nanomolar agonists of A1R (99-
Despite this extensive literature with unnatural analogs, it is surprising that the most biologically relevant substitution – a 5’-phosphate – has never, to our knowledge, been directly tested as an A_1R agonist.

Our data also revealed that a different adenosine receptor – hA_{2B}R – is not activated by AMP or the non-hydrolyzable analog ACP. Instead, hA_{2B}R was only activated indirectly, following hydrolysis to adenosine. These results shed light on seemingly conflicting reports of AMP acting directly as well as indirectly on adenosine receptors in some tissues but only indirectly via conversion to adenosine in other tissues (65,71-73,103,104). Our data indicate that it is important to determine which adenosine receptor is activated when AMP is used as the ligand. If A_{2B}R is activated, the signaling effects of AMP should be indirect and fully dependent on ectonucleotidases. In contrast, if A_1R is activated, the signaling effects of AMP could be direct and indirect, with the level of direct activation dependent on AMP stability and ectonucleotidase levels.

We found that a non-hydrolyzable phosphonate analog of AMP could activate hA_1R. Interestingly, other ectonucleotidase-resistant phosphonate analogs of AMP reportedly activate P2X receptors and have cardioprotective activity in vivo (105,106). While it was suggested that the cardioprotective effects of these AMP analogs were due to P2X activation, P2X involvement was never directly tested in vivo with antagonists or knockout mice. Given that A_1R agonists also have cardioprotective effects (61), it is equally possible that the cardioprotective effects of these phosphonate analogs, and possibly AMP itself, are A_1R-mediated and not P2X-mediated.
Our findings also have implications for AMP-based prodrugs that were designed to be full agonists for $A_{2A}\text{R}$ only after hydrolysis by ectonucleotidases (107). Given our results and the extensive structure-activity data with substitutions at the 5’-position, these AMP prodrugs may display a complex pharmacology with direct $A_{1}\text{R}$ activation combined with indirect, hydrolysis-dependent $A_{2A}\text{R}$ activation. Clearly, it will be important to rigorously evaluate the extent to which these and other AMP-based prodrugs activate $A_{1}\text{R}$ independent of hydrolysis. This will require pharmacologically or genetically eliminating all of the AMP hydrolytic enzymes in a given tissue – a potentially daunting task given that numerous ectonucleotidases are present in complex tissues and are difficult to experimentally eliminate completely (79).
CHAPTER 3: FURTHER INVESTIGATION OF A_1R SIGNALING

INTRODUCTION

The results presented in Chapter 2 raise several significant questions regarding the function of adenosine receptors. Firstly, what causes the difference in AMP sensitivity between the A_1 and A_2B receptors? Agonist sensitivity of GPCRs is usually thought to be determined by the residues in the receptor’s agonist binding site; that is, the residues that directly interact with the agonist in the final, activated conformation. However, as detailed in Chapter 2, these residues are essentially completely conserved between the human A_1 and A_2B receptors (and therefore cannot be responsible for the difference in AMP sensitivity). Thus, the molecular mechanism(s) that determine the AMP sensitivity of adenosine receptors remains unknown.

Secondly, what explains AMP’s lack of \textit{in vivo} antinociceptive activity? The initial experiments in Chapter 2 (Fig. 2.2) were originally undertaken in order to better understand the activity of the pain-relieving ectonucleotidases prostatic acid phosphatase (PAP) and NT5E. These enzymes reduce pain sensitivity when administered intrathecally (70,76) – or peripherally in the case of PAP (108) – by generating adenosine in situ. The substrate for both enzymes is AMP, which is present in the extracellular environment at much higher levels than adenosine (109). Furthermore, the effects of both PAP and NT5E are mediated by the A_1 adenosine receptor. Taken together with the results from Chapter 2, this brings to light an apparent paradox: if AMP and adenosine are equipotent A_1R agonists (Fig. 2.6), why
does conversion of one into the other have any A₁R-mediated effect at all? Nevertheless, direct intrathecal injection of adenosine generates transient antinociceptive effects but injection of AMP does not (Dutton and Zylka, unpublished data), indicating that there is indeed a difference between AMP and adenosine in vivo.

Lastly, there is great interest in the development of A₁ adenosine receptor agonists as pharmaceuticals. In recent years there have been numerous A₁ agonists in clinical trials for conditions as diverse as cardiac arrhythmia, angina, diabetes, and neuropathic pain (98). However, none of these compounds are based on an AMP scaffold. Furthermore, many promising A₁ agonists have encountered difficulties in clinical trials due to severe cardiovascular side effects and loss of efficacy due to A₁ receptor desensitization (98). Thus, the therapeutic potential of AMP-derived A₁R agonists (and whether they will be subject to these problems) is worthy of further investigation.

Here, we set out to answer the above questions regarding adenosine receptor activity, primarily by adapting the calcium mobilization assay used extensively in chapter 2. We found that the difference in AMP sensitivity between the human A₁ and A₂B receptors is at least partially determined by the sequence of the second extracellular loop, which likely affects the ability of AMP to access the agonist binding pocket by influencing the electrical charge on the extracellular face of the receptor. Additionally, we found that although AMP and adenosine are equally potent and equally efficacious hA₁R agonists through the Gαᵢ-coupled pathway, they exhibit dramatically different efficacies at hA₁R through the Gα₁₅-coupled pathway. This difference, or differential activation of other downstream effectors, is likely responsible for the discrepancy between AMP- and adenosine-evoked effects in vivo. Finally, we found that several AMP analogues are also potent hA₁R agonists, and that one of
these compounds does indeed have significant A₁R-mediated antinociceptive activity in mice. Furthermore, this compound lacks the characteristic cardiovascular side effects caused by many adenosine receptor agonists, indicating that there may be therapeutic applications for AMP-derived drugs in the treatment of pain.
MATERIALS AND METHODS

Molecular Biology

The human Gαq expression construct was a gift from Dr. Bryan Roth. A1R/A2bR loop-replacement chimeras were generated by traditional PCR-based mutagenesis and were sequence verified. All other expression constructs were described previously (110). ACP, 3a, and 3d were synthesized as described previously (110,111).

Calcium Imaging

All calcium mobilization experiments and the data analysis thereof were performed as described previously (110).

Telemetry

Data Sciences International ETA-F20 transmitters were implanted as follows: A 2 cm midline abdominal incision was made in anesthetized mice. The transmitter was placed intra-abdominally on top of the intestines, parallel with the long axis of the body and the two leads pointing caudally. A large (14 gauge) needle was used to pass through the abdominal muscles on either side of the incision. The leads were passed through the lumen of the needle, one on each side and the needle was withdrawn. The leads were placed (positive by
the xiphoid and negative on the right pectoral) and anchored in place. The abdomen was closed with absorbable sutures and the skin with non-absorbable sutures.

Note: Figures 3.3 and 3.4, and the methods and results sections referring to them, are adapted from Korboukh et al (111) and constitute my personal contributions to that study.
RESULTS

*Adenosine receptor sensitivity to AMP is partially determined by extracellular loop 2*

We first set out to determine why the hA₁ receptor is sensitive to AMP but the hA₂B receptor is not, despite the fact that the residues in their respective binding pockets are nearly identical (11). Although the amino acid sequences of the transmembrane helices are highly conserved between hA₁R and hA₂B R, the sequences of the extracellular loops (ELs) diverge significantly (Fig. 3.1A). In fact, the net charge of the solvent-exposed extracellular faces of hA₁R and hA₂B R is very different, due to the composition of these loops (Fig. 3.1B). Furthermore, we previously found that negative charge was important in the activation of hA₁R by AMP (110). We therefore hypothesized that the relative AMP sensitivities of the hA₁ and hA₂B receptors may be determined by their extracellular charge.

In order to test this hypothesis, we created A₁/A₂B chimeric receptors in which EL1, EL2, or ELs 1 and 2 from hA₁R were replaced with the equivalent loops from hA₂B R. We focused on ELs 1 and 2 because a homology model based on the crystal structure of the human A₂A receptor (11) predicts that these loops are located in much closer proximity to the agonist binding pocket than either EL3 or the N terminus (not shown). Furthermore, the net charge in EL3 does not vary between hA₁R and hA₂B R (Fig. 3.1B), suggesting that mutagenesis of this loop is likely to have little effect. We then co-transfected the A₁/A₂B chimeras together with Gqi into HEK293 cells and measured calcium mobilization after stimulation with multiple concentrations of AMP. We performed these experiments in the presence of 10 μM αβ-met-ADP, to block the hydrolysis of AMP into adenosine.
We found that AMP potency and efficacy were very similar between WT hA$_1$R (Fig. 3.1C, *pink*; EC$_{50} = 1.11$ µM, E$_{\text{max}} = 27.0$) and the EL1 chimera (Fig. 3.1C, *orange*; EC$_{50} = 1.25$ µM, E$_{\text{max}} = 22.8$), suggesting that EL1 does not play a significant role in determining the AMP sensitivity of hA$_1$R and hA$_{2\beta}$R. However, AMP potency and efficacy were both drastically reduced in the EL2 chimera (Fig. 3.1C, *olive*; EC$_{50} = 65.3$ µM, E$_{\text{max}} = 10.8$), indicating that EL2 is a regulator of AMP sensitivity. The EL1,2 chimera (Fig. 3.1C, *green*; EC$_{50} = 28.3$ µM; E$_{\text{max}} = 9.6$) responded similarly to the EL2 chimera, again suggesting that EL1 is not involved in AMP sensitivity. As expected, we did not observe a calcium response after stimulating cells expressing WT hA$_{2\beta}$R with any concentration of AMP (Fig. 3.1C, *blue*). The potency and efficacy of adenosine was similar at WT hA$_1$R and each of the chimeras (data not shown), indicating that modification of EL2 does not affect general receptor function. There are likely other determinants of adenosine receptor AMP sensitivity, as the loss of AMP sensitivity in the EL2 and EL1,2 chimeras was not complete. However, our data strongly suggest that the composition of EL2 is an important determinant of AMP sensitivity in hA$_1$R and hA$_{2\beta}$R, likely by influencing the electrostatic charge immediately outside the agonist binding pocket.
Figure 3.1

A

<table>
<thead>
<tr>
<th>N-term.</th>
<th>EL1</th>
<th>EL2</th>
<th>EL3</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>hA_1R</td>
<td>+1</td>
<td>-1</td>
<td>+2</td>
<td>+2</td>
</tr>
<tr>
<td>hA_2B</td>
<td>-2</td>
<td>-1</td>
<td>-3</td>
<td>+2</td>
</tr>
<tr>
<td>△ Charge</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

B

+ 10 μM αβ-met-ADP

Area Under Curve (F340/F380) x s

-8 -7 -6 -5 -4 -3

log [AMP], M

WT hA_1
hA_1 - (EL1)_2B
hA_1 - (EL2)_2B
hA_1 - (EL1,2)_2B
WT hA_2B
Figure 3.1. Adenosine receptor sensitivity to AMP is partially determined by extracellular loop 2.

A) Amino acid sequence alignment of hA1R and hA2B. * Yellow, transmembrane domain. Red, negatively charged residue. Green, positively charged residue. *, identical residues in hA1R and hA2B. :, similar residues in hA1R and hA2B. Grey box, N-terminus. Blue box, extracellular loop 1. Red box, extracellular loop 2. Green box, extracellular loop 3. B) Comparison of net charge in the extracellular regions of hA1R and hA2B. C) Calcium mobilization in HEK293 cells expressing the indicated A1/A2B chimeras + Gqi and stimulated with AMP. WT hA1: EC50 = 1.11 µM; Emax = 27.0. hA1-(EL1)2B: EC50 = 1.25 µM; Emax = 22.8. hA1-(EL2)2B: EC50 = 65.3 µM; Emax = 10.8. hA1-(EL1,2)2B: EC50 = 28.3 µM; Emax = 9.6. For all conditions, cells were incubated with 10 µM αβ-met-ADP for 3 minutes and then stimulated in the presence of 10 µM αβ-met-ADP. AUC measurements extended for 1 minute from AMP addition. n = 11-43 cells per condition. All data are presented as mean ± standard error.
AMP and adenosine differentially activate Gαq through the A1 adenosine receptor

Administration of prostatic acid phosphatase (PAP) causes A1R-mediated antinociceptive effects by hydrolyzing AMP to adenosine in situ (76). Additionally, intrathecal injection of adenosine causes short-lived antinociceptive effects, whereas intrathecal injection of AMP does not (Dutton and Zylka, unpublished data). These results appear to conflict with our evidence that adenosine and AMP are equipotent A1R agonists (Fig. 2.6). However, although primarily coupled to Gαi, hA1R is a ‘promiscuous’ GPCR, meaning that it can couple to multiple G proteins, including Gαs, and Gαq (112). In fact, an adenosine analog with a bulky substituent at the 5’ position (similar to 5’-AMP) causes selective activation of Gαi over Gαq by A1R (112). Furthermore, PAP’s antinociceptive effects are mediated by the depletion of PIP2 (113), a pathway downstream of Gαq. Thus, we hypothesized that differential activation of Gαq downstream of A1R may explain AMP’s lack of antinociceptive activity, despite its A1 agonist activity.

To examine hA1R activation of Gαq, we repeated our adenosine and AMP calcium mobilization experiments, replacing the chimeric G protein Gqi with wild-type human Gαq. We found that in cells expressing hA1R + Gαq, stimulation with 1 mM AMP (Fig. 3.2 A,B; blue) evoked a much smaller calcium response compared to stimulation with 1 mM adenosine (Fig. 3.2 A,B; red). This is a striking difference from the assay employing Gqi, in which adenosine and AMP evoked identical responses (Fig. 2.2). Since Gαq is ubiquitously expressed, and should be present in HEK293 cells without overexpression, we also performed the experiment without transfecting Gαq. In cells expressing only hA1R, stimulation with 1mM adenosine (Fig. 3.2 A,B; green) evoked a very small calcium
response, and stimulation with 1 mM AMP (Fig. 3.2 A,B; *orange*) evoked no response at all, consistent with a much lower level of Gαq expression.

We then examined the relative potency and efficacy of adenosine and AMP through Gαq by repeating our dose-response experiments in the same fashion. We found that in cells expressing hA1R + Gαq adenosine (Fig. 3.2C, *red*; EC50 = 8.97 µM, Emax = 18.0) had moderately reduced potency and efficacy compared to cells expressing hA1R + Gqi (compare Fig. 3.2C to Fig. 2.6), consistent with preferential coupling of hA1R to Gαi. Moreover, the efficacy of AMP (Fig. 3.2C, *blue*; EC50 = 7.69 µM; Emax = 7.90) was far lower than that of adenosine in cells expressing hA1R + Gαq, although the potencies of adenosine and AMP were similar. Again, this is a very different result from the assay employing Gqi, in which both the potencies and efficacies of adenosine and AMP were essentially identical (Fig. 2.6).

We did not observe significant calcium mobilization in cells expressing hA1R + Gαq after stimulation with 1 mM ACP (Fig. 3.2C, *black*), consistent with ACP’s low efficacy compared with AMP. Taken together, these data suggest that adenosine and AMP may still have different effects in vivo – despite being equally potent and equally efficacious A1R agonists through Gαi – via differential activation of other downstream signaling pathways, including Gαq.
Figure 3.2

A. 1 mM Agonist

B. Area Under Curve (F340/F380) x s

C. Area Under Curve (F340/F380) x s vs. log [Agonist], M
Figure 3.2. Adenosine and AMP have similar potencies but very different efficacies when stimulating hA1R activation of Gαq.

Calcium mobilization in HEK293 cells expressing hA1R. A) Real-time calcium mobilization profiles in cells expressing hA1R + Gαq or hA1R alone and stimulated with 1 mM adenosine or AMP. n = 54-75 cells per condition. B) AUC quantification of calcium mobilization. C) Adenosine and AMP dose responses in cells expressing hA1R + Gαq. Adenosine: EC50 = 8.97 µM; Emax = 18.0. AMP: EC50 = 7.69 µM; Emax = 7.90. n = 14-53 cells per condition. AUC measurements extended for 1 minute from agonist addition. ***, p < 0.0005. All data are presented as mean ± standard error.
AMP analogues are potent A₁R agonists

In order to investigate whether compounds similar to AMP have A₁R agonist activity and/or antinociceptive activity, we synthesized a series of AMP analogues containing an N⁶-cyclopentyl group, which is known to confer A₁R subtype selectivity (114). Nearly all of these compounds were potent agonists of hA₁R in a cAMP accumulation assay identical to the one presented in Figure 2.7 (111). We then selected compounds 3a (Fig. 3.3A, a representative phosphate ester) and 3d (Fig. 3.3B, a representative phosphate) and tested them in the hA₁R + Gqi calcium mobilization assay. The Eₘₐₓ of 3a and 3d were normalized to the Eₘₐₓ of adenosine in this assay. Both 3a (Fig. 3.3C, pink) and 3d (Fig. 3.3C, orange) were potent agonists of hA₁R with EC₅₀ values of 0.52 μM and 0.021 μM, respectively. Furthermore, the Eₘₐₓ of 3a and 3d were similar to that of adenosine, indicating that 3a and 3d are full agonists at hA₁R. Therefore, using two distinct and complementary assay platforms, we confirmed that compounds 3a and 3d directly activate A₁R-mediated signaling.
Figure 3.3

A

B

3a

3d

C

Area Under Curve (% Adenosine)

log [Agonist], M
Figure 3.3. Compounds 3a and 3d are full agonists of human A\textsubscript{1}R in a calcium mobilization assay.

A and B) Chemical structures of (A) 3a and (B) 3d at physiological pH. C) Calcium mobilization in HEK293 cells expressing hA\textsubscript{1}R + Gqi and stimulated with the indicated compounds. 3a: EC\textsubscript{50} = 0.52 μM; and 3d: EC\textsubscript{50} = 0.021 μM. Adenosine (EC\textsubscript{50} = 1.41 μM) was used as a positive control. AUC measurements extended for 1 minute from agonist addition. n = 27-50 cells per condition. All data are presented as mean ± standard error.
An AMP analogue has antinociceptive activity and lacks cardiovascular side effects in mice

Further experiments with our series of AMP analogues revealed that compound 3a has potent A₁R-mediated antinociceptive effects in mice when administered orally or by intrathecal injection (111). However, clinical applications of the currently available A₁R agonists are hampered by their cardiovascular side effects (98). To determine if compound 3a affected cardiovascular function, we monitored heart rate and body temperature in wild-type and A₁R⁻/⁻ mice following oral administration (CPA was administered as a positive control). At the highest dose tested, a 5000 nmol/kg (2.39 mg/kg) single dose by oral administration, compound 3a had no to negligible effects on heart rate and body temperature in wild-type and A₁R⁻/⁻ mice (Fig. 3.4 A,C). On the other hand, CPA elicited a statistically significant decrease in heart rate and body temperature which lasted for 4 to 6 hours in wild-type mice (Fig. 3.4 B,D), but not in A₁R⁻/⁻ mice. CPA caused a modest increase in heart rate in A₁R⁻/⁻ mice, possibly reflecting known off-target activation of stimulatory A₂ receptors (100,115). Collectively, our results indicate that our novel A₁R agonist 3a has potent antinociceptive effects but minimal to no cardiovascular side effects when administered orally at a high 5000 nmol/kg dose. In contrast, the same high dose of CPA has antinociceptive effects and significant cardiovascular side effects. These data suggest that 3a has a large therapeutic window, and uniquely lacks cardiovascular side-effects that are associated with other A₁R agonists like CPA.
Figure 3.4

A. 3a - Heart Rate

B. CPA - Heart Rate

C. 3a - Body Temperature

D. CPA - Body Temperature
Figure 3.4. Compound 3a does not have long-lasting effects on heart rate or body temperature while CPA causes a significant decrease in heart rate and body temperature in wild-type mice.

A and C) Effects of 3a on (A) heart rate and (C) body temperature in wild-type (red) and A1R−/− (black) mice. B and D) Effects of CPA on (B) heart rate and (D) body temperature in wild-type (red) and A1R+/− (black) mice. Compounds were orally administered at 5000 nmol/kg immediately before telemetry recording began. n = 8 C57BL/6 male mice per group for A1R+/− body temperature measurements, 6 male mice per group for all other conditions.
DISCUSSION

We found that the difference in AMP sensitivity between hA1R and hA2B R is partially determined by the composition of extracellular loop 2, as replacement of EL2 in hA1R with the EL2 from hA2B R caused a dramatic drop in both AMP potency and efficacy (Fig. 3.1C). Differences in ligand binding interactions are unlikely to mediate this effect, as no hA1R-hA2B R divergent residues in EL2 interact with AMP while it is in the hA1R binding pocket (based on our hA1R homology model, derived from the crystal structure of hA2A R). Rather, this effect is likely due to electrostatic repulsion, as the EL2 of hA2B R is more negatively charged than that of hA1R (Fig. 3.1B), and AMP is a negatively charged ligand. Interestingly, replacement of EL1 instead of or in addition to EL2 had no effect on AMP potency or efficacy (Fig. 3.1C), despite the fact that EL1 and EL2 have the same net charge difference between hA1R and hA2B R (Fig. 3.1B). This suggests that extracellular loop position is also critical in influencing AMP sensitivity. In our hA1R homology model EL2 is located immediately outside of the agonist binding pocket (in fact, a conserved phenylalanine residue in EL2 forms a π-stacking interaction with the purine moiety of adenosine (11)), while the other extracellular portions of hA1R are located farther away. We therefore propose that the negatively charged EL2 of hA2B R acts as a ‘gatekeeper’, restricting the access of anionic ligands (such as AMP) to the binding pocket, but allowing neutral ligands (such as adenosine) to pass freely.

Notably, the composition of EL2 is not responsible for the entire difference in AMP sensitivity between hA1R and hA2B R, as the EL2 and EL1,2 chimeric receptors retain some level of activity in response to AMP stimulation (Fig. 3.1C). The origin of this remaining AMP sensitivity is not known. One possibility is that the remaining sensitivity is determined
by the composition of the N-terminus, which was not mutated in our study. However, there is reason to believe that this is not the case. As mentioned above, in our hA1R homology model, EL2 is located immediately outside the agonist binding pocket. Among the remaining extracellular portions of hA1R, EL3 is located the closest to the binding pocket, EL1 is located at an intermediate distance, and the N-terminus is located at the greatest distance. Since mutation of EL1 had no effect on AMP sensitivity, it is unlikely that mutation of the N-terminus, which has the same net charge difference as EL1 (Fig. 3.1B) but is located farther from the agonist binding pocket, would have any significant effect. In a similar fashion, the composition of EL3 is likely not relevant, as although it is located relatively close to the agonist binding pocket, it is well-conserved and possesses an identical net charge in both hA1R and hA2B R (Fig. 3.1B).

The other possibility is that AMP sensitivity is also partly due to differences in G protein coupling between A1R and A2B R. A1R primarily couples to Gαi, whereas A2B R primarily couples to Gαs, although coupling to additional Gα subunits has been described for both receptors (112,116-118). The characteristic G protein-coupling interfaces of hA1R and hA2B R are determined by the sequences of the intracellular loops, which are divergent between the two receptors (Fig. 3.1A). Furthermore, AMP binds to the hA1R binding pocket through an interaction with histidine 251, whereas adenosine does not (Fig. 2.11D). This unique binding interaction implies that the A1 receptor adopts a distinct conformation upon the binding of each ligand. It is therefore possible that binding of AMP in the hA1R binding pocket causes a conformational shift which is sufficient to cause full activation of Gαi, but that this same conformational shift in hA2B R causes no or limited activation of Gαs. Further investigation of this potential mechanism is warranted, but would entail mutagenesis of the
hA1R intracellular loops. This would by definition change the coupling properties of the receptor, and likely necessitate the development of new downstream assays to measure receptor activity.

The recently-discovered phenomenon by which a single agonist, binding to a single GPCR, preferentially activates some downstream signaling pathways over others is known as functional selectivity (35,119). Although the concept was first recognized less than 10 years ago, the potential implications of functional selectivity on drug discovery has quickly led to a significant body of work on the subject. As such, functionally selective ligands have now been identified for multiple GPCRs (120-125), including the A1 and A3 adenosine receptors (112,126). However, the vast majority of such studies have focused on synthetic agonists, as opposed to biological signaling molecules.

Here, we have shown that the physiologically relevant nucleotide AMP is a functionally selective agonist at the human A1 receptor. AMP is a full agonist (i.e. its maximal response is equivalent to that of adenosine) of Gαi-coupled signaling through hA1R (Fig. 2.6), but only a partial agonist (i.e. a saturating agonist concentration elicits a smaller response than a saturating concentration of adenosine) of Gαq-coupled signaling through the same receptor (Fig. 3.2). This is not dependent on overexpression of Gαq, as we also observed greater adenosine-evoked responses using endogenously expressed G proteins (Fig. 3.2 A,B; green). In fact, at endogenous levels of Gαq expression, AMP may not stimulate Gαq-coupled signaling through hA1R at all (Fig. 3.2 A,B; orange).

This effect is not caused by a deficiency in AMP binding to hA1R, as AMP has comparable potency to adenosine, even via pathways for which it is only a partial agonist.
Rather, this effect is caused by deficient signal transduction between the intracellular face of hA1R and its associated G protein. As discussed above, AMP and adenosine binding to hA1R generates two unique receptor conformations, as AMP forms a unique interaction with at least one residue in the hA1R binding pocket (Fig 2.11D). Our data indicate that the AMP-induced conformation strongly promotes activation of Gαi, but only weakly promotes activation of Gαq. In support of this mechanism, another hA1R agonist with a bulky 5’ substituent – the binding of which is therefore likely to cause a similar receptor conformation to that caused by the binding of AMP – also causes preferential activation of Gαi (112).

It is important to note that while adenosine is assumed to be a universal full agonist at A1R, this may not necessarily be the case. There are other pathways activated downstream of A1R through which adenosine and AMP have not been compared, including Gαs-coupled and β-arrestin mediated signaling. It is possible that AMP is a more efficacious A1R agonist than adenosine through another downstream effector. Indeed, the discovery of functional selectivity has largely made obsolete the simple concept of a ‘full agonist’, and our results underscore the necessity of measuring multiple pathways downstream of GPCR activation in order to obtain a more complete understanding of a given compound’s true agonist activity.

We found that compound 3a (Fig. 3.3A) has potent antinociceptive activity in mice when delivered by intrathecal injection (111), while AMP (Fig. 2.4A) does not. Although the basis for this difference in activity is not known, the structures of the two compounds are very similar. In fact, there are only three structural modifications between AMP and 3a that could be responsible: 3a is a dimethyl ester, rather than a charged phosphate, and it contains both a 2-chloro and an N6-cyclopentyl group attached to the adenine moiety. It is unlikely
that the addition of the methyl groups – which eliminates both negative charges from the 5’-phosphate group – is responsible for 3a’s activity, as elimination of even one negative charge from the 5’-phosphate (in the compound ACP, Fig. 2.4B), had a deleterious effect on efficacy at hA1R (Fig. 2.6). Indeed, compound 3d (Fig. 3.3B), which lacks these methyl groups, also has antinociceptive activity in mice (Coleman and Zylka, unpublished data).

The other set of modifications made to AMP to yield compound 3a are the addition of 2-chloro and N⁶-cyclopentyl groups. These groups were derived from the compound CCPA, an exceptionally potent (Fig. 2.6) and highly selective A1R agonist (114). As the pain-relieving effects of adenosine agonists are A1R-mediated (98), these ‘CCPA-like’ groups were added to some of our AMP analogues in an attempt to enhance A1R activity (111). This effort was successful, as the ‘CCPA-like’ compounds 3a and 3d both displayed higher potency at hA1R than adenosine in the calcium mobilization assay (Fig. 3.3C). Of these two substituents, the 2-chloro group appears to be less important, as another AMP analogue similar to 3a but lacking the 2-chloro group also had antinociceptive activity via intrathecal injection (Coleman and Zylka, unpublished data). Thus, it appears that the N⁶-cyclopentyl ring is the critical structural component conveying in vivo antinociceptive activity to the AMP scaffold.

Furthermore, we found that oral administration of compound 3a (Fig. 3.4 A,C) did not cause the cardiovascular side effects characteristic of A1R agonists (Fig. 3.4 B,D; CPA used as representative A1R agonist). This difference in side effect profile was unexpected, as depression of heart rate and body temperature is A1R-mediated (Fig. 3.4 B,D; compare wild-type C57BL/6, red, to A1R⁻/⁻, black), and 3a is a potent A1R agonist (Fig 3.3C) (111). Interestingly, intracerebroventricular injection of an A1R agonist was recently shown to
severely depress heart rate and body temperature in rats (127), suggesting that the cardiovascular effects of A₁R agonists are at least partially mediated by the central nervous system (CNS). Since 3a was administered orally in this experiment, this raises the possibility that 3a may lack cardiovascular side effects because it cannot cross the blood-brain barrier and access the CNS. However, A₁R agonists also have direct inhibitory effects on the heart itself. Thus, the lack of cardiovascular effects may be caused by differential signaling downstream of A₁R, as 3a has only been evaluated in Gα_i-coupled assays of A₁R activity.

The other problem that has plagued A₁R agonists in the clinic – the rapid development of tolerance due to A₁ receptor desensitization (98) – has not been evaluated using AMP-derived agonists. GPCR desensitization is largely mediated by β-arrestin signaling (128), which is activated in a distinct fashion from G protein-mediated signaling (21). Once again, this suggests that differential activation of multiple downstream signaling pathways may be critical in determining if AMP-derived A₁R agonists realize their therapeutic potential. The ideal A₁R-mediated pain therapeutic will need to be CNS-impermeable – to avoid cardiovascular side effects as much as possible, although specific activation of antinociceptive A₁ receptors over those in the heart may prove to be an impossible task, at least with systemic drug administration – and functionally selective towards G protein signaling over β-arrestin signaling, to avoid the development of tolerance. Thus, whether focusing on 3a, other AMP analogues, or structurally unrelated A₁R agonists, additional work is needed to determine if these compounds are CNS-penetrant and to fully characterize their A₁R agonist activity.
CHAPTER 4: OVEREXPRESSION OF DIACYLGlycerol KINase ETA
PROLONGS GPCR SIGNALING

INTRODUCTION

Diacylglycerol kinases (DGKs) are a large family of enzymes that catalyze the phosphorylation of the membrane lipid diacylglycerol (DAG) to phosphatidic acid (PA) (129,130). Both DAG and PA are important second messengers and regulate diverse proteins and pathways, including protein kinase C (PKC) (30,131), ion channels (132), endocannabinoid production (133), and phosphatidylinositol synthesis (134). Thus, by affecting the levels of DAG and PA, DGKs are well positioned to regulate diverse intracellular signaling pathways (135).

In recent years, a number of studies have identified genetic associations between DGKH and bipolar disorder (BPD) (136-141). DGKH is the gene that encodes diacylglycerol kinase eta (DGKη). Moreover, Moya and colleagues found that DGKη mRNA was expressed at higher levels in post-mortem tissue samples from patients with BPD than unaffected controls (142). DGKη is a Type II DGK isoform with two known splice variants (143-145), and was recently implicated in lung cancer (146). However, how alterations in DGKη levels might affect cellular functions or contribute to BPD pathogenesis is currently unknown.
Dysregulation of G protein-coupled receptor (GPCR) activity is involved in the pathology of many psychiatric disorders, including BPD (147). Indeed, tissues from BPD patients exhibit changes in GPCR (148) and G protein subunit (149,150) expression, enhanced receptor-G protein coupling (151), and decreased expression of a GPCR-regulating kinase (150). Furthermore, therapeutic concentrations of lithium and valproate, common treatments of BPD, inhibit G protein activation after GPCR stimulation in cell membranes (152) and platelets from bipolar patients (153).

Given that DGKn is expressed at higher levels in BPD patients and has the potential to affect GPCR signaling, we sought to determine if overexpression of DGKn affected GPCR signaling in HEK293 cells, a model cell line with well-characterized GPCR signaling cascades (154). Here, we found that overexpression of DGKn dramatically prolonged the duration of calcium responses after stimulating endogenous Gαq-coupled GPCRs. This DGKn-mediated effect was dependent on DGKn catalytic activity and was abolished after depleting multiple PKC isoforms. Taken together, our data indicate that DGKn prolongs GPCR signaling by attenuating PKC activity and suggest this occurs by attenuating PKC-dependent receptor desensitization.
MATERIALS AND METHODS

Materials

Carbamoylcholine chloride (carbachol, C4382), D-sorbitol (S1876), n-butanol (B7906), ethylenediaminetetraacetic acid (EDTA, EDS), phenylmethanesulfonyl fluoride (PMSF, P7626), sodium fluoride (201154), DL-dithiothreitol (DTT, D0632), sodium deoxycholate (D6750), adenosine 5'-triphosphate disodium salt (ATP, A7699), HEPES sodium salt (H7006), glycerol (G7893), sodium pyrophosphate (P8135), Dulbecco’s phosphate buffered saline (PBS, D8537), and fatty acid-free BSA (A6003) were purchased from Sigma-Aldrich. Concentrated hydrochloric acid (A144SI), Tris hydrochloride (Tris-HCl, BP153), sodium chloride (NaCl, BP358), magnesium chloride hexahydrate (MgCl₂, BP214), Triton X-100 (BP151), Tween 20 (BP337), and D-glucose (D16) were purchased from Fisher Scientific. Nonidet P40 substitute was acquired from USB Corporation (NP40, 19628). [γ-³²P]-labeled ATP (6000 Ci/mmol, 150 mCi/ml) was obtained from Perkin Elmer (NEG035C005MC).

Molecular Biology

A full-length clone of mouse DGKη isoform 1 was generated by PCR amplification using cDNA from C57BL/6 mouse neurons as a template (bases 1-3471 from GenBank accession #NM_001081336.1) (143). The initial clone was found to be unstable due to high GC content at the 5’ end of the DGKη coding sequence. To remedy this problem, the first 70 bases of the DGKη coding sequence were modified to decrease GC content while preserving the wild-type (WT) DGKη amino acid sequence (native sequence: ATGGCCGGGG
CCGCCAGCCA GCACCACCCT CAGGGCGTCG CGGGAGGAGC GGTCGCTGGG
GCCAGCGCGG; modified sequence: ATGGCAGGAG CAGGAAGTCA GCATCATCCT
CAGGGAGTTG CAGGAGGAGC AGTTGCAGGA GCAACTGCAG). The resulting
construct was stable and was used to generate all subsequent constructs. DGK\(\eta\) truncation
constructs were generated by PCR amplification. The G389D point mutant was generated by
traditional PCR-based mutagenesis. Full-length DGK\(\eta\) and all DGK\(\eta\) constructs were
inserted into the multiple cloning site of pcDNA 3.1(+) downstream of monomeric RFP
lacking a stop codon, to create fusion constructs with N-terminal RFP tags. A DGK\(\eta\)-646\(\Delta\)
fusion construct with an N-terminal Venus tag was generated in the same fashion. All
constructs contained a Kozak consensus sequence and were sequence verified.

*Cell Culture*

HEK293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; Gibco,
11995) containing 10% fetal bovine serum, 100 U/ml penicillin, and 100 \(\mu\)g/ml streptomycin
at 37°C and 5% CO\(_2\). Cells were plated on polylysine-coated glass-bottom dishes (MatTek,
P35G-0-10-C) for calcium imaging, polylysine-coated glass coverslips (Brain Research
Laboratories, 2222) for immunostaining, and polylysine-coated 6-well plates (Corning, 3516)
for all other experiments. Twenty-four hours after plating, cells were transfected with
Lipofectamine/Plus (Invitrogen) in serum-free DMEM according to the manufacturer’s
instructions. Each plate/well was transfected with 500 ng of each DNA construct, and the
total amount of DNA per transfection was normalized to 1 \(\mu\)g with empty vector. After 4
hours, the transfection medium was replaced with fresh growth medium. To deplete PKC
isoforms, cells were treated overnight with 300 nM phorbol 12-myristate 13-acetate (PMA; Sigma, P8139) in growth medium (155). All experiments except those measuring ERK phosphorylation were performed 24 hours after transfection. For experiments measuring ERK phosphorylation, 24 hours after transfection, the growth medium was replaced with serum-free DMEM and cultured for an additional 24 hours.

Calcium Imaging

Calcium imaging was performed as described previously (110). Briefly, HEK293 cells expressing various DGKη constructs and controls were washed twice in HBSS assay buffer (Invitrogen #14025, supplemented with 9 mM HEPES, 11 mM D-glucose, and 0.1% fatty acid-free BSA, pH 7.3) and loaded with 2 µM Fura-2 AM (Invitrogen, F-1221) in 0.02% Pluronic F-127 (Invitrogen, P3000-MP) in assay buffer for 1 hour at room temperature. Cells were then washed three times in assay buffer, incubated at room temperature for 30 minutes, and imaged on a Nikon Eclipse Ti microscope. A Sutter DG-4 light source and Andor Clara CCD camera were used to image calcium responses. 500-ms excitation at 340 nm and 250-ms excitation at 380 nm was used for all experiments. Fura-2 emission was measured at 510 nm.

Fresh assay buffer was added prior to each experiment. After 40 seconds of baseline imaging, the assay buffer was aspirated and agonist solution was added. All solutions were aspirated and pipetted manually. For experiments involving overnight treatment with PMA, 300 nM PMA was present in all loading and wash solutions. Only cells that expressed visible RFP fluorescence, had low baseline Fura-2 ratios (< 0.6), and responded to agonist
stimulation (Fura-2 ratio $> 0.8$ at any time after agonist addition) were analyzed. For experiments using cells transfected with RFP-DGK$\eta$-$\Delta$645 and Venus-DGK$\eta$-646$\Delta$, only cells expressing both visible RFP fluorescence and visible Venus fluorescence were analyzed. Real-time response profiles and area under curve (AUC) values were generated as described previously (110). To control for day-to-day variation in calcium responses, control cells expressing RFP alone were tested as part of each experiment. AUC values were then normalized such that RFP alone was set at a value of 1.

**Confocal Microscopy**

HEK293 cells expressing RFP-DGK$\eta$ were washed twice in HBSS assay buffer and imaged using a Yokogawa CSU-10 spinning disc confocal scanner mounted on a Nikon TE2000 microscope. An Argon/Krypton laser light source and a Hamamatsu Orca-ER camera were used to image RFP-tagged DGK$\eta$. After approximately 1 minute of baseline imaging, assay buffer was replaced with buffer containing $10 \mu$M carbachol or $500 \text{ mM sorbitol}$, and imaging continued for an additional 15 minutes. Solutions were removed and added by manual pipetting.

**Immunostaining**

HEK293 cells expressing RFP were incubated in PBS alone or $300 \text{ nM PMA}$ in PBS for 10 minutes at $37^\circ\text{C}$ then fixed in ice-cold $4\%$ paraformaldehyde (Fisher, T353) for 15 minutes. After incubating in $0.5\%$ Triton X-100 in PBS for 15 minutes, coverslips were
blocked for 30 minutes in blocking solution [0.1% Triton X-100 and 5% normal goat serum (Invitrogen, PCN5000) in PBS] then incubated with Rabbit anti-PKCδ primary antibody (Santa Cruz Biotechnology, sc-937) in blocking solution overnight at 4°C. Cells were then washed with 10% goat serum in PBS for 30 minutes and incubated in Alexa Fluor 488-conjugated Goat anti-Rabbit secondary antibody (Invitrogen, A11008) and DRAQ5 nuclear dye (Cell Signaling, 4084S) in blocking solution for 1 hour at room temperature. Cells were washed three times (5 minutes/wash) with PBS between each step. Coverslips were mounted onto microscope slides (Fisher, 12-550-143) with Fluoro-Gel (Electron Microscopy Sciences, 17985-10) and stored at 4°C until imaging. Slides were imaged the following day on a Zeiss LSM 510 microscope, with Multiline Argon and Helium-Neon laser light sources and a 63x objective.

**Phospho-ERK Western Blotting**

HEK293 cells expressing RFP alone or RFP-DGKη were cultured overnight in serum-free growth medium, then incubated with agonist (or vehicle) in serum-free growth medium for 5 minutes at 37°C. Cells were then quickly washed with ice-cold PBS, and phosphoprotein lysis buffer was added [20 mM HEPES pH 7.4, 150 mM NaCl, 10 mM EDTA, 3 mM sodium pyrophosphate, 1% Triton X-100, 1x Complete Mini protease inhibitor cocktail (Roche, 11 836 153 001), 1x Phosphatase Inhibitor Cocktail 2 (Sigma, P5726)]. After buffer addition, cells were frozen at -80°C and left overnight. The lysed cells were thawed on ice and collected, and the lysates were clarified by centrifugation at 10,000g for
15 minutes at 4°C. Protein content of the clarified lysates was measured using a BCA assay kit (Thermo, 23227) according to the manufacturer’s instructions.

A portion (20 µg) of each lysate was heated at 94°C for 5 minutes with an appropriate amount of 4x Laemmli sample buffer, and separated by SDS-PAGE on a 4-15% gradient gel (Bio-Rad, 456-1083) at 100 V for 1 hour. Proteins were transferred to a PVDF membrane (Bio-Rad, 162-0174) at 100 V for 70 minutes on ice, and blocked with 5% nonfat milk (Bio-Rad, 170-6404) in TBST (100 mM Tris-HCl pH 7.5, 165 mM NaCl, 0.1% Tween 20) for 1 hour at room temperature. Blots were then incubated with Rabbit anti-phospho-ERK (Cell Signaling, 4370S) or anti-total-ERK (Cell Signaling, 4695S) primary antibodies in 5% BSA (Sigma, A3912) in TBST overnight at 4°C. The following day, blots were washed three times (5 minutes/wash) with TBST and incubated with IRDye800-conjugated Donkey anti-Rabbit secondary antibody (LI-COR, 926-32213) in 5% nonfat milk/TBST for 1.5 hours at room temperature. Blots were then washed three times (5 minutes/wash) with TBST and imaged on a LI-COR Odyssey CLx infrared imaging system. Phospho-ERK and total-ERK blots were imaged simultaneously under identical conditions. Band intensity was quantified using ImageJ image analysis software (National Institutes of Health).

Co-immunoprecipitation

HEK293 cells expressing tagged DGKη truncation constructs or fluorescent tags alone were washed twice with ice-cold PBS and scraped into glycerol-Co-IP buffer containing 50 mM HEPES pH 7.4, 250 mM NaCl, 2 mM EDTA, 10% (v/v) glycerol, 0.5% (v/v) NP40, 1x protease inhibitor cocktail, and 1x phosphatase inhibitor cocktail. Cellular
debris was removed by centrifugation at 10,000g for 10 minutes at 4°C and input aliquots of the clarified lysate were set aside. The remaining lysate was then incubated with Chicken anti-GFP primary antibody (Aves Labs, GFP-1020) or normal Chicken IgY control (Santa Cruz, sc-2718) for 3 hours at 4°C with gentle mixing. Agarose beads coupled to Goat anti-Chicken IgY (Aves, P-1010) were then added to each sample and incubated for 1 hour at 4°C. The beads were washed four times (5 minutes/wash) with ice-cold glycerol Co-IP buffer, and bound proteins were eluted from the beads by incubation with Laemmlili sample buffer for 15 minutes at 37°C. Input and IP fractions were then separated by SDS-PAGE, transferred to PVDF membrane, and blotted as described above, using Rabbit anti-RFP primary antibody (Invitrogen, R10367). After imaging, blots were re-probed with Rabbit anti-GFP primary antibody (Invitrogen, A11122) to determine the specificity of the precipitation. Samples containing RFP alone were heated for 5 minutes at 94°C before SDS-PAGE; samples containing RFP-DGKη constructs were not heated, because we found that DGKη protein and DGKη truncation constructs were undetectable on western blots when heated at 94°C.

**In-vitro Kinase Assay**

The DGK in vitro kinase assay was adapted from previous studies (156,157). HEK293 cells expressing RFP-tagged DGKη (WT or truncation constructs) or RFP alone were washed twice with ice cold PBS and scraped into lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1x protease inhibitor cocktail, 1x phosphatase
inhibitor cocktail). Cells were disrupted by brief sonication on ice, and debris was collected by centrifugation at 10,000g for 10 minutes at 4°C. Clarified lysates were kept on ice.

The final reaction mixture contained 50 mM Tris-HCl pH 7.4, 100 mM NaCl, 20 mM NaF, 10 mM MgCl₂, 1 mM DTT, 1 mM EDTA, 1 mM sodium deoxycholate, 0.5 mM DAG (8:0, 12:0, or 18:1), 1 mM [γ-³²P]ATP (50 µCi/rxn), and lysate; reaction volume was 50 µl. A calculated amount of 1,2-dioctanoyl-glycerol (8:0 DAG), 1,2-dilauroyl-glycerol (12:0 DAG), or 1,2-dioleoyl-glycerol (18:1 DAG) in chloroform (Avanti Polar Lipids; 800800C, 800812C, and 800811C respectively) was deposited in a glass tube under a stream of dry nitrogen gas. The DAG was then resuspended in an appropriate amount of 5x kinase buffer (250 mM Tris-HCl pH 7.4, 500 mM NaCl, 100 mM NaF, 50 mM MgCl₂, 5 mM DTT, 5 mM EDTA) and 10 mM sodium deoxycholate by brief bath sonication. 15 µl of the DAG suspension was added to a tube containing 20 µl of water, followed by 5 µl of 10 mM [γ-³²P]ATP. The reaction was initiated by adding 10 µl of lysate, incubated for 3 minutes at 30°C, and then stopped by adding 25 µl of 12 N HCl followed by 750 µl of water saturated with n-butanol. Lipids were extracted from the reaction mixture by adding 500 µl of n-butanol, mixing thoroughly, and separating by centrifugation at 1,000g for 5 minutes. 450 µl of the organic phase was washed with 500 µl of n-butanol-saturated water and separated by centrifugation, with care taken not to disturb the aqueous phase. 350 µl of this organic phase was then washed again in the same fashion. Finally, 250 µl of the washed organic phase was transferred to a scintillation vial containing 2 ml of ScintiSafe Econo 2 (Fisher, SX21-5) scintillation fluid, mixed gently, and counted on a LKB Wallac Rackbeta 1209 liquid scintillation counter.
For experiments comparing different DGKη truncation constructs, 15 µl of each lysate sample used in the in-vitro kinase assay was analyzed by western blotting with Rabbit anti-RFP antibody as described above, and the band intensity was quantified. The DGKη activity data were corrected for differences in expression, and normalized such that RFP alone was set at a value of 0, and wild-type DGKη was set at a value of 1.
RESULTS

*Mouse DGKη phosphorylates multiple DAG substrates*

First, we set out to evaluate whether mouse DGKη isoform 1 was catalytically active (Fig. 4.1A shows domain structure of isoform 1). To accomplish this, we transfected HEK293 cells with RFP-tagged DGKη or RFP only (control) expression constructs. One day later, we prepared cell lysates, incubated these lysates with purified DAG substrates and [$\gamma$-32P]ATP, then monitored 32P-labeled phosphatidic acid (PA) formation (Fig. 4.1B). This in vitro assay was previously used to monitor DGK activity (156,157). We found that kinase reactions containing RFP-DGKη produced significantly more 32P-PA than reactions containing RFP alone (Fig. 4.1C) when 500 µM dioctanoyl (8:0), dilauroyl (12:0), or dioleoyl (18:1) glycerol was used as substrate. Given that mouse DGKη could phosphorylate multiple DAG substrates, and that 18:1 DAG was previously used to characterize human DGKη and other DGK isoforms (143), we elected to use 18:1 DAG for subsequent experiments. The K$_m$ of DGKη for 18:1 DAG was 18.4 µM (Fig. 4.1D), justifying our use of a saturating 500 µM DAG concentration for subsequent in vitro kinase reactions.

*DGKη prolongs intracellular calcium mobilization after GPCR stimulation*

Since DGKη is expressed at higher levels in patients with bipolar disorder (142), we next sought to determine if overexpression of DGKη affects endogenous GPCR signaling. We focused our research on HEK293 cells because they endogenously express the M$_3$ muscarinic acetylcholine receptor, a Gα$_q$-coupled GPCR that mobilizes intracellular calcium following stimulation with carbachol (154). Moreover, M$_3$ receptor desensitization and
downstream signaling pathways have been extensively studied (154,158-162). After stimulating with 10 µM carbachol, we found that the calcium mobilization response was dramatically prolonged in HEK293 cells expressing RFP-DGKη compared to RFP alone (Fig. 4.1E). Based on quantifying the area under the curve (AUC), the carbachol-evoked calcium response in RFP-DGKη-expressing cells was 80% greater than in cells expressing RFP alone (p < 0.0005). The N-terminal RFP tag did not affect DGKη activity, as untagged DGKη, HA-DGKη, and DGKη-mCherry also prolonged carbachol-evoked calcium responses (data not shown; we identified cells with untagged or HA-tagged DGKη by co-transfecting with Venus, a yellow fluorescent protein).

We next investigated whether DGKη could prolong calcium mobilization downstream of other Gαq-coupled GPCRs. To accomplish this, we stimulated HEK293 cells with 10 µM ATP, which elicits intracellular calcium mobilization by activating endogenous P2Y receptors (110). We found that HEK293 cells expressing RFP-DGKη exhibited dramatically prolonged ATP-evoked calcium responses compared to cells expressing RFP alone (Fig. 4.1F). When quantified by AUC, ATP-evoked calcium responses in RFP-DGKη-expressing cells were 81% greater than responses in cells expressing RFP alone (p < 0.005). These data indicate that overexpression of DGKη can enhance calcium responses downstream of two different GPCRs. Since calcium mobilization was more pronounced (longer duration) following endogenous M₃ receptor activation, we focused the remainder of our experiments on DGKη modulation of M₃ receptor activation.
Figure 4.1. Mouse DGKη is catalytically active and prolongs GPCR signaling.

A) Domain architecture of DGKη. PH = Pleckstrin Homology. C1 = PKC homology domain 1. aa = amino acid. B) Schematic of the reaction forming $^{32}$P-labeled PA from DAG and radiolabeled ATP. C) Full-length mouse RFP-DGKη is catalytically active. Lysates from HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη were incubated with the indicated DAG substrates, each at 500 µM. D) $^{32}$P-PA production from reactions containing the indicated concentrations of 18:1 DAG, catalyzed by lysates from HEK293 cells expressing RFP-DGKη. Data were normalized to the signal in the absence of DAG substrate and fit to a Michaelis-Menton curve. E and F) Calcium mobilization in HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη after stimulation with (E) 10 µM carbachol or (F) 10 µM ATP. AUC measurements extended for 4 minutes from agonist addition. Data in C and D are the average of two experiments performed in duplicate. Data in E and F are the average of three independent experiments; n = 41-104 cells per condition. Paired t tests were used to compare data. **, p < 0.005; ***, p < 0.0005. All data, including calcium traces, are presented as means ± standard error.
DGKη catalytic activity is required to prolong carbachol-evoked calcium mobilization

DGKη, like all type II DGK isoforms, possesses a split catalytic domain (130). To determine if DGKη catalytic activity was required to prolong carbachol-evoked calcium mobilization, we generated two DGKη deletion constructs, DGKη-Δ645 and DGKη-646Δ, each containing one half of the catalytic domain (Fig. 4.2A). We also generated DGKη-G389D, containing a point mutation that is predicted to abolish ATP binding based on homology to other DGK proteins (163). We found that DGKη-Δ645, DGKη-646Δ and DGKη-G389D were expressed (Fig. 4.3, Fig. 4.2E) but were catalytically inactive, as they generated no more 32P-PA than lysates containing RFP alone (Fig. 4.2B). In contrast, lysates from cells co-expressing DGKη-Δ645 and DGKη-646Δ displayed specific activity approximately 32% of that of wild-type (WT) RFP-DGKη (Fig. 4.2B), suggesting the two halves directly interact. Indeed, we found that RFP-DGKη-Δ645 co-immunoprecipitated with Venus-DGKη-646Δ (Fig. 4.2C). This interaction was specific to DGKη-Δ645 and DGKη-646Δ and did not involve the fluorescent tags or non-specific binding to the immunoprecipitation beads, as evidenced by controls showing no interaction when either construct was replaced with a fluorescent protein alone or when the anti-GFP antibody was replaced with an IgY control (Fig. 4.2C).

Additionally, none of these catalytically dead constructs (DGKη-Δ645, DGKη-646Δ or DGKη-G389D) prolonged calcium mobilization after carbachol stimulation (Fig. 4.2D). Cells expressing DGKη-646Δ alone appeared unhealthy and displayed a slight reduction in calcium mobilization. In contrast, co-expression of each half of DGKη (RFP-tagged DGKη-Δ645 and Venus-tagged DGKη-646Δ) increased calcium mobilization by 62% (based on
AUC measurement, Fig. 4.2D). Our data clearly indicate that DGKη catalytic activity is required to prolong carbachol-evoked calcium mobilization.

We also tested the catalytic activity of several DGKη truncation mutants lacking structural domains (Fig. 4.4A). We found that the PH domain and C-terminal tail negatively regulated DGKη catalytic activity and that the C1 domains were required for catalytic activity (Fig. 4.4 B,D). Furthermore, catalytic activity closely correlated with the ability to prolong carbachol-evoked calcium mobilization (Fig. 4.4C).

We next analyzed calcium mobilization AUC data on a cell-by-cell basis, to determine if the expression level of DGKη correlated with how effectively DGKη prolonged calcium mobilization responses. Notably, there was no relationship between the level of DGKη expression and the extent of calcium mobilization in cells expressing WT DGKη or kinase-dead DGKη-G389D (Fig. 4.2E). There was also no significant difference in the expression level of WT DGKη and DGKη-G389D across individual cells. Similarly, no correlation between DGKη expression and calcium mobilization was observed for any of the DGKη truncation constructs (Figs. 4.3 & 4.4; data not shown). Taken together, these data suggest that the amount of DGKη required to maximally prolong carbachol-evoked calcium mobilization is very small, perhaps because only a small amount of DAG substrate is generated upon M3 receptor activation. In support of this possibility, we did not detect an increase in DAG levels after activating the endogenous M3 receptor with carbachol (with a sensitive DAG biosensor—Upward DAG2, data not shown) (164).
Figure 4.2

A

WT DGKn

DGKn-Δ645

DGKn-646Δ

B

Relative Specific DGK Activity (Arbitrary Units)

 chiffon

C

IB: α-RFP

Input α-GFP IP

IB: α-GFP

Venus-646Δ

D

Normalized Area Under Curve (Arbitrary Units)

E

Normalized Area Under Curve (Arbitrary Units)

Relative DGKn Expression (Pixel Intensity Units)
**Figure 4.2.** DGKη catalytic activity is required to prolong GPCR signaling.

A) Structure of the DGKη truncation constructs used. DGKη-G389D contains a point mutation in catalytic domain A (not shown). All DGKη constructs were N-terminally tagged with RFP unless otherwise noted. B) Production of $^{32}$P-PA in reactions containing lysates from HEK293 cells expressing the indicated DGKη constructs, using 500 µM 18:1 DAG as substrate. Data were normalized to DGKη expression, which was assessed by western blotting against RFP, then normalized so that RFP alone = 0 and WT DGKη = 1. Data are the average of two experiments performed in duplicate. C) N- and C-terminal halves of DGKη interact. Lysates from HEK293 cells expressing RFP-tagged DGKη-Δ645 and Venus-tagged DGKη-646Δ or fluorescent protein controls were immunoprecipitated using an anti-GFP antibody or an IgY control. Input and precipitated fractions were then run on SDS-PAGE and blotted using an anti-RFP antibody. The blot was later re-probed with an anti-GFP antibody to verify the specificity of the immunoprecipitation. D) AUC measurements of calcium mobilization in HEK293 cells expressing the indicated DGKη constructs after stimulation with 10 µM carbachol, normalized such that RFP alone = 1. AUC data for the RFP and WT DGKη conditions is also presented, in non-normalized form, in Fig. 4.1E. Data are the average of three to six independent experiments. n = 58-162 cells per condition, except DGKη-646Δ, where n = 23. E) Scatter plot comparing calcium mobilization AUC measurements to DGKη expression levels in individual HEK293 cells expressing (red) WT DGKη or (gray) DGKη-G389D. Horizontal dashed line indicates average level of calcium mobilization in HEK293 cells expressing RFP alone. Vertical dashed line indicates average expression level of WT DGKη. Paired t tests were used to compare data. *Black asterisks* indicate a statistically significant difference when compared
with RFP alone. *Red asterisks* indicate a statistically significant difference when compared to WT DGKη. *, p < 0.05; **, p < 0.005; ***, p < 0.0005. All data are presented as means ± standard error.
Figure 4.3
Figure 4.3. Expression of DGKη truncation constructs in HEK293 cells.

HEK293 cells expressing the indicated DGKη constructs were lysed and western blotted using an anti-RFP antibody. All DGKη constructs were N-terminally tagged with RFP.
Figure 4.4

[Diagram showing various domains and their effects on kinase activity]

A. Domain structure

B. Relative specific DEK activity

C. Area under the curve

D. Domain structure and kinase activity

---

Normalized

Arbitrary units

---

103
Figure 4.4. Catalytic activity and signaling effects of DGKη truncation constructs.

A) Domain architecture of the indicated DGKη constructs. All constructs are N-terminally tagged with RFP. Δ645, 646Δ, and G389D constructs are discussed in Figure 4.2. 

B) Production of $^{32}$P-PA in reactions with the indicated DGKη constructs, using 500 µM 18:1 DAG as substrate. Data were normalized to DGKη expression, which was assessed by western blotting against RFP, then normalized so that RFP alone = 0 and WT DGKη = 1. Data are the average of two experiments performed in duplicate. In the enzymatic assay, the PH domain and the C-terminal tail of DGKη appear to have negative regulatory activity, as truncation of either domain led to increased specific activity. The construct lacking both domains, 161Δ961, has a specific activity 6-fold higher than WT DGKη. Both constructs lacking C1 domains were inactive. As observed previously, the long splice isoform DGKη2 had decreased catalytic activity relative to DGKη1 (143). 

C) AUC measurements of calcium mobilization in HEK293 cells expressing the indicated DGKη constructs after stimulation with 10 µM carbachol, normalized such that RFP alone = 1. Data were not normalized to expression, as there was no relationship between expression and signaling effect for any of the DGKη constructs (data not shown, and see Fig. 4.2E). Data are the average of three to six independent experiments. n = 75-209 cells per condition. In the signaling assay, truncation of the PH domain also resulted in a small increase in activity. However, truncation of the C-terminal tail had no effect on activity in DGKη constructs with C1 domains. The 317Δ construct lacking C1 domains was inactive, but truncating the C-terminal tail from this construct restored some degree of signaling activity. DGKη2 had a very low level of activity, statistically indistinguishable from RFP alone (p = 0.057). 

D) Speculative model of DGKη regulatory domain function; based on data from in vitro
enzymatic assays. CT = C terminal tail. Truncation of the PH domain or the C-terminal tail increases specific activity, suggesting that these domains inhibit the catalytic activity of DGK\(\eta\), perhaps by restricting access of DAG and/or ATP to the DGK\(\eta\) active site (although not completely, as WT DGK\(\eta\) retains activity). Inhibition by the PH domain and C terminal tail appear to be independent, as truncation of both domains increases catalytic activity in an additive manner. The C1 domains are required for activity in this assay, as loss of the C1 domains results in a complete loss of catalytic activity. The SAM domain (not shown in Panel D, present only in DGK\(\eta2\)) also negatively regulates DGK\(\eta\) activity, possibly by enhancing inhibition by the C terminal tail. Paired t tests were used to compare data. Black asterisks, statistically significant difference when compared with RFP alone. Red asterisks, statistically significant difference when compared to WT DGK\(\eta\). *, p < 0.05; **, p < 0.005; ***, p < 0.0005. All data are presented as means ± standard error.
DGK\(\eta\) does not affect ER calcium loading or store-operated calcium entry

Next, to determine if DGK\(\eta\) prolonged calcium responses by affecting intracellular calcium stores, we treated RFP-DGK\(\eta\)-expressing cells and RFP-expressing controls with thapsagargin, a non-competitive sarco/endoplasmic reticulum calcium ATPase (SERCA) inhibitor that causes release of intracellular calcium stores into the cytosol (165,166). Calcium release was not significantly different between cells expressing RFP alone and RFP-DGK\(\eta\) (Fig. 4.5A), indicating that DGK\(\eta\) has no effect on the loading of intracellular calcium stores.

When intracellular calcium stores become depleted, calcium-sensing proteins trigger the opening of calcium channels in the plasma membrane, allowing the entry of extracellular calcium, a process known as store-operated calcium entry (167,168). To determine if DGK\(\eta\) prolonged calcium mobilization by affecting this process, we stimulated cells with carbachol in the absence of extracellular calcium (to abolish calcium entry through store-operated channels). In the absence of extracellular calcium, carbachol-evoked calcium mobilization was reduced, particularly in the later stages of the response (compare Fig. 4.5B to Fig. 4.1E). However, overexpression of DGK\(\eta\) still prolonged the calcium response by 77% (based on AUC measurements) when compared to RFP alone. This effect was nearly identical to the 80% AUC increase in the presence of extracellular calcium. Thus, these data indicate that DGK\(\eta\) prolongs the carbachol-evoked calcium response via a mechanism that is independent of store-operated calcium entry.
Figure 4.5

(A) 1 μM Thapsigargin

Intracellular Ca$^{2+}$

$\Delta(F_{340}/F_{380})$

Time (s)

RFP Only

RFP-DGKn

Area Under Curve

$(F_{340}/F_{380}) \times$s

(B) 10 μM Carbachol

Intracellular Ca$^{2+}$

$\Delta(F_{340}/F_{380})$

Time (s)

0 $[Ca^{2+}]_e$

RFP Only

RFP-DGKn

Area Under Curve

$(F_{340}/F_{380}) \times$s

***
Figure 4.5. DGKη does not affect intracellular calcium stores.

Calcium mobilization in HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη after (A) stimulation with 1 µM thapsigargin or (B) stimulation with 10 µM carbachol in the absence of extracellular calcium. AUC measurements extended 8 minutes (A) or 4 minutes (B) after stimulation. Paired t tests were used to compare AUC data. ***, p < 0.0005. Data are the average of two (A) or five (B) independent experiments. n = 69-190 cells per condition. All data, including calcium traces, are presented as means ± standard error.
**DGK\(\eta\) does not translocate after GPCR stimulation**

Human DGK\(\eta\) localizes to the cytosol under baseline conditions and translocates to endosomes after osmotic shock (143,169). However, whether DGK\(\eta\) translocates to the plasma membrane, where DAG is located, following GPCR stimulation is unknown. Using live cell confocal imaging, we found that mouse DGK\(\eta\) is localized throughout the cytoplasm in unstimulated cells and did not translocate to the plasma membrane or any other subcellular compartment after stimulation with 10 \(\mu\)M carbachol (Fig. 4.6A). This experiment was conducted under conditions that were identical to those used in the carbachol-evoked calcium mobilization assay, suggesting that the prolonged effects of DGK\(\eta\) on GPCR signaling require little if any translocation of DGK\(\eta\) to the plasma membrane. Furthermore, we were unable to detect translocation of DGK\(\eta\) when cells were stimulated with 10 \(\mu\)M or 100 \(\mu\)M carbachol at 37\(^\circ\)C (data not shown). Our inability to detect DGK\(\eta\) translocation was not a technical limitation, as our mouse DGK\(\eta\) construct rapidly translocated to endosomes after osmotic shock (Fig. 4.6B), as previously shown using human DGK\(\eta\) (143,169).

**DGK\(\eta\) prolongs GPCR signaling via attenuating PKC activation**

DAG is a canonical activator of conventional and novel isoforms of PKC (30). Additionally, PKC is directly and indirectly involved in the phosphorylation and subsequent desensitization of GPCRs (44,170,171). Therefore, we hypothesized that DGK\(\eta\) could prolong GPCR signaling by metabolizing DAG and hence reducing PKC activation. To test this hypothesis, we used the phorbol ester PMA, which potently activates PKC (172). First, we confirmed that acute treatment with 300 nM PMA could activate PKC\(\delta\) in HEK293 cells,
as evidenced by rapid (within 2 minutes) translocation of PKCδ to the plasma membrane (Fig. 4.7A). We then measured calcium mobilization after stimulating RFP- and RFP-DGKη-expressing cells with 300 nM PMA followed immediately by 10 µM carbachol. Stimulation with 300 nM PMA profoundly accelerated the return of carbachol-evoked calcium mobilization to baseline (Fig. 4.7B, compare to Fig. 4.1E). Furthermore, the carbachol-evoked calcium responses were identical in cells expressing RFP alone and RFP-DGKη when PKC was acutely activated with 300 nM PMA (Fig. 4.7B). In contrast, stimulation of RFP-expressing cells with 300 nM PMA alone did not evoke a calcium response (Fig. 4.7B). Taken together, these data indicate that PKC activation blunts GPCR signaling in HEK293 cells and occludes the effect of DGKη.

We next took advantage of the fact that overnight stimulation with PMA is reported to lead to the near complete depletion of all PKC isoforms that are expressed in HEK293 cells (155) except one (PKCδ was not tested in this reference). We examined PKCδ and found that it was also significantly depleted by overnight stimulation with 300 nM PMA (Fig. 4.7C). Furthermore, after culturing HEK293 cells overnight in 300 nM PMA, stimulation with 10 µM carbachol elicited identical calcium responses in cells expressing RFP alone and RFP-DGKη (Fig. 4.7D). This was not due to a lack of DGKη, as there was no decrease in RFP-DGKη expression in cells cultured in 300 nM PMA compared to cells cultured in DMEM alone (data not shown). Instead, these data indicate that DGKη potentiates GPCR signaling via PKC, likely by reducing the levels of a PKC activator (DAG) and attenuating PKC activity.
Figure 4.6

A  

<table>
<thead>
<tr>
<th>10 µM Carbachol</th>
</tr>
</thead>
<tbody>
<tr>
<td>T = 0'</td>
</tr>
<tr>
<td><img src="image1.png" alt="Images of cells at different times" /></td>
</tr>
</tbody>
</table>

B  

<table>
<thead>
<tr>
<th>500 mM Sorbitol</th>
</tr>
</thead>
<tbody>
<tr>
<td>T = 0'</td>
</tr>
<tr>
<td><img src="image1.png" alt="Images of cells at different times" /></td>
</tr>
</tbody>
</table>
Figure 4.6. DGKη does not translocate within cells after GPCR stimulation.

Confocal images of live HEK293 cells expressing RFP-DGKη after stimulation with (A) 10 µM carbachol or (B) 500 mM sorbitol for the indicated times. Cell culture and imaging conditions were identical to those used in calcium mobilization experiments. Panel (A) shows cells from independent experiments.
Figure 4.7

A

No Stimulation

300 nM PMA

α-PKCα

DRAQ5

B

10 µM Carbachol

300 nM PMA

Intracellular Ca²⁺

\[ \Delta (F340/F380) \]

Time (s)

0 40 80 120 160 240 280 320

Area Under Curve

(F340/F380) x s

RFP Only
PMA + CCh
RFP-DGKα
PMA + CCh
PMA Only

***

C

Ladder
DMEM
300 nM PMA

IB: α-PKCα

IB: α-β-Actin

Normalized PKCα

DMEM
300 nM PMA

***

D

10 µM Carbachol

300 nM PMA Overnight

Intracellular Ca²⁺

\[ \Delta (F340/F380) \]

Time (s)

0 40 80 120 160 240 280

Area Under Curve

(F340/F380) x s

RFP Only
RFP-DGKα
Figure 4.7. DGKη prolongs GPCR signaling via PKC.

A) PKCδ translocation following PMA stimulation. Confocal images of HEK293 cells after treatment with (left) vehicle or (right) 300 nM PMA for 2 minutes. Cells were fixed, immunostained with an anti-PKCδ antibody (green), and counterstained with DRAQ5 nuclear dye (blue). B) Calcium mobilization in HEK293 cells expressing RFP alone or RFP-DGKη after stimulation with (black, red) 300 nM PMA followed by 10 µM carbachol, or (blue) 300 nM PMA alone. AUC measurements extended 80 seconds from final agonist addition. Data are the average of two (PMA alone) or three (PMA + carbachol) independent experiments. n = 49-83 cells per condition. C) HEK293 cells were cultured overnight in growth medium ± 300 nM PMA to deplete PKC isoforms. Cells were lysed and 20 µg of protein from each lysate was run on SDS-PAGE and blotted using anti-PKCδ and anti-β-actin antibodies. (Right) Band intensities were quantified using ImageJ. Data are the average of three independent experiments. Overnight PMA treatment was previously shown to deplete all other PKC isoforms in HEK293 cells (155). D) Calcium mobilization in HEK293 cells expressing (black) RFP alone or (red) RFP-DGKη, after overnight culture in media containing 300 nM PMA. Cells were stimulated with 10 µM carbachol. AUC measurements extended 4 minutes from agonist addition. Data are the average of four (RFP-DGKη) or five (RFP alone) independent experiments. n = 28-35 cells per condition. Paired t tests were used to compare all data. ***, p < 0.0005. All data, including calcium traces, are presented as means ± standard error.
DGK\textsubscript{\texteta} reduces baseline and GPCR agonist-evoked ERK phosphorylation

Carbachol-evoked phosphorylation of ERK is mediated by PKC\textdelta in HEK293 cells (154). Thus, we next evaluated the extent to which overexpression of DGK\texteta affected ERK phosphorylation. We treated HEK293 cells expressing RFP or RFP-DGK\texteta with vehicle, 10 \textmu M carbachol, or 300 nM PMA for 5 minutes, lysed the cells, and then ran western blots using a phospho-specific anti-ERK primary antibody (Fig. 4.8A). After treatment with vehicle or 10 \textmu M carbachol, RFP-DGK\texteta cell lysates contained less phospho-ERK than lysates from RFP alone cell lysates (Fig. 4.8B). The DGK\texteta-evoked decrease in ERK phosphorylation was modest (approximately 20\%), but statistically significant (p < 0.05), both at baseline and after carbachol stimulation. This likely reflects the fact that not every cell was transfected with RFP-DGK\texteta. In contrast, after direct stimulation of PKC with 300 nM PMA, which bypasses the need for DAG to activate PKC, there was no difference in ERK phosphorylation between lysates from cells expressing RFP alone and RFP-DGK\texteta (Fig. 4.8B). Taken together, these data indicate that overexpression of DGK\texteta reduces ERK phosphorylation.
Figure 4.8

A

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>10 μM CCh</th>
<th>300 nM PMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>RFP</td>
<td>DGKη</td>
<td>RFP</td>
<td>DGKη</td>
</tr>
<tr>
<td>IB: α-pERK</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IB: α-ERK</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

![Graph showing pERK/ERK values for different treatments](chart)

- **RFP Only**
- **RFP-DGKη**

* denotes statistical significance.
Figure 4.8. DGKη reduces baseline and GPCR agonist-evoked phosphorylation of ERK.

A) After serum-starvation (no serum) for 24 hours, HEK293 cells expressing RFP or RFP-DGKη were treated with vehicle, 10 µM carbachol, or 300 nM PMA for 5 minutes then were lysed. 20 µg of protein from each lysate was run on SDS-PAGE and blotted using anti-phospho ERK and anti-ERK antibodies. B) Band intensities were quantified using ImageJ and pERK/ERK ratios were calculated. Paired t tests were used to compare data. *, p < 0.05. Data are the average of four experiments performed in duplicate. All data are presented as means ± standard error.
Figure 4.9

A

GPCR → Ga_q → PIP_2 → PLC → DAG → IP_3 → Ca^{2+}

ERK ← PKC

B

GPCR → Ga_q → PIP_2 → PLC → DAG → DGK_η → PA

ERK ← PKC

IP_3 ↑ Ca^{2+}
Figure 4.9. Model showing how DGKη prolongs Gaq-coupled GPCR signaling.

A) Activation of Gaq-coupled GPCRs leads to the stimulation of PLC-catalyzed hydrolysis of PIP2 and the release of IP3 and DAG. IP3 activates IP3 receptors on the endoplasmic reticulum, resulting in the release of intracellular calcium stores. Concurrently, DAG activates conventional and novel isoforms of PKC, leading to the phosphorylation of ERK by MAP kinase cascades. Additionally, PKC activity leads to the phosphorylation of activated GPCRs, resulting in receptor desensitization and the attenuation of GPCR signaling. B) After receptor activation, overexpressed DGKη reduces the pool of free DAG by converting it into PA, thus suppressing the activation of PKC. Decreased PKC activity leads to reduced phosphorylation of ERK. As previously shown (173-176), reduced PKC activity attenuates GPCR desensitization. This leads to prolonged IP3 and intracellular calcium release following receptor activation.
DISCUSSION

Collectively, our data suggest a model for how DGKη prolongs GPCR signaling (Fig. 4.9). Stimulation of Gαq-coupled GPCRs leads to the activation of phospholipase C (PLC) and the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP$_2$) into inositol 1,4,5-triphosphate (IP$_3$) and DAG. IP$_3$ subsequently induces the release of endoplasmic reticulum calcium stores, raising the cytosolic concentration of Ca$^{2+}$. In cells without DGKη activity (Fig. 4.9A), DAG activates PKC, leading to the phosphorylation and desensitization of the activated GPCR, followed by termination of GPCR signaling (170,173,174). Activated PKC also signals through other downstream pathways, including MAPK cascades which culminate in ERK phosphorylation. However, in cells overexpressing DGKη, DAG is phosphorylated to PA, leading to a decreased level of PKC activation (Fig. 4.9B, red). This causes a decrease in the rate of GPCR phosphorylation and desensitization, resulting in prolonged GPCR signaling (as evidenced by sustained intracellular calcium release). Reduced PKC activity also leads to reduced activation of MAPK cascades, resulting in decreased phosphorylation of ERK.

We focused on PKCδ because it is highly expressed (177) and mediates ERK phosphorylation (154) in HEK293 cells, and because it preferentially activates GRK2, a regulator of GPCR signaling (171). Moreover, PKCδ is a Ca$^{2+}$-insensitive isoform of PKC (30), and thus would not be affected by prolonged calcium responses.

During activation, PKC isoforms translocate to the plasma membrane (178), and are autophosphorylated at multiple amino acid residues (179,180). We attempted to measure PKC activation directly via: 1) PKCδ immunostaining (Fig. 4.7A), 2) membrane/cytosol fractionation and PKCδ western blotting (181), 3) anti-phospho-PKCδ western blotting.
(182), 4) anti-pan-phospho-PKC western blotting (183), and 5) a FRET biosensor of PKC activity (184). Unfortunately, we did not observe endogenous PKC activation with any of these techniques after stimulation of endogenous receptors with carbachol, and were therefore unable to measure the effect of DGKη on endogenous PKC activity. This did not reflect technical limitations, as we did observe endogenous PKCδ activation after direct stimulation with PMA (Fig. 4.7A). Instead, our inability to directly measure endogenous PKC activity suggests very little PKC is activated when endogenous receptors are stimulated. Indeed, previous studies that measured PKC activity employed overexpressed receptors (181,183). It is well-documented that overexpressed receptors activate signaling pathways at non-physiological (excessive) levels relative to endogenous receptor activation (185). This is precisely why we used endogenous M₃ receptors and a sub-EC₅₀ concentration of carbachol (154) in our signaling experiments, to probe potential negative and positive modulation at physiological levels of GPCR activation.

Alternatively, it is possible that 10 µM carbachol selectively stimulates the strong activation of a single PKC isoform other than PKCδ, which does not phosphorylate either itself or the PKC biosensor. However, it is far more likely that stimulation of endogenous M₃ receptors in HEK293 cells simply results in a very low level of DAG release and PKC activation. Indeed, only a minimal level of DGKη expression results in the full DGKη-mediated signaling effect (Fig. 4.2E), consistent with a very small amount of available substrate. Nevertheless, modulation of PKC activity clearly mediates the effect of DGKη on GPCR signaling, as both activation (Fig. 4.7B) and depletion (Fig. 4.7D) of PKC blocks overexpressed DGKη from prolonging endogenous M₃ receptor activation. Furthermore,
after signal amplification downstream of PKC by the Raf-MEK-ERK cascade, activation by 10 µM carbachol and suppression by DGKη were observed (Fig. 4.8B).

It is well-established that PKC activation leads to desensitization of GPCRs (170,173,174). Based on this literature, we propose that overexpression of DGKη prolongs GPCR signaling by attenuating PKC-mediated phosphorylation and desensitization of GPCRs (Fig. 4.9). Such a mechanism should have a greater effect on the duration of calcium responses than the intensity, as we observed (Fig. 4.1 E,F). Likewise, cholinergic stimulation of cells expressing a phosphorylation-deficient M₃ receptor resulted in prolonged calcium mobilization compared to cells expressing wild-type M₃ receptor (186), strongly resembling the effect of overexpressed DGKη on the M₃ receptor. Although PKC directly phosphorylates some GPCRs (44,170), phosphorylation of the M₃ receptor in HEK293 cells is likely indirect, through the activation of G protein-coupled receptor kinases (GRKs). In HEK293 cells, M₃ receptor activity is regulated by GRKs 2, 3, and 6 (154), at least one of which is activated by PKC (171,187,188). Interestingly, GRK3 is also genetically linked to BPD (150), suggesting that dysregulation of GPCR signaling is important in the pathology of BPD.

Like DGKη, other DGK isoforms regulate PKC and receptor signaling. For example, disruption of the gene encoding DGKδ leads to DAG accumulation, enhanced PKC activity and EGFR phosphorylation (189), culminating in a PKC-dependent increase in EGFR ubiquitination and degradation (190). DGKs also regulate inter-receptor desensitization pathways, as DGKθ attenuates bradykinin-evoked, PKC-mediated phosphorylation of EGFR, a phosphorylation event that is linked to EGFR desensitization (191). Interestingly, EGFR is a receptor tyrosine kinase, indicating that regulation of receptor signaling by DGKs is not
limited to GPCRs. Together with our study, it is clear that multiple members of the DGK enzyme family regulate PKC activity and receptor signaling.

Lastly, there are several connections between DGKη-regulated signaling pathways and BPD. Patients with BPD show increased levels of PKC activity compared to unaffected controls, which can be inhibited by the mood stabilizers lithium and valproate (153,192-194). In fact, there is clinical interest in PKC inhibitors as treatments for BPD (195-199). Based on our current study, increased DGKη activity should reduce PKC activity, suggesting that increased DGKη expression does not contribute to BPD simply by regulating global PKC activity. The DGKη product PA is also a critical intermediate in the phosphatidylinositol cycle, another proposed therapeutic target of lithium (200-202). Interestingly, three polymorphisms in the DGKη gene which are linked to BPD are not correlated with responsiveness to lithium therapy (203), although this does not rule out lithium-sensitive pathways in the role of DGKη in BPD. Future studies are needed to delineate precisely how DGKη activity is altered in BPD patients and how alterations in DGKη levels affect PKC and GPCR signaling in neurons and in animal models of BPD.
CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS

Perhaps the most fundamental result to come out of my graduate work is the discovery that the physiologically relevant nucleotide AMP is an adenosine A$_1$ receptor agonist (see Chapter 2). AMP was previously known to have some signaling activity, primarily via stimulation of AMP-activated protein kinase, an important intracellular regulator of energy homeostasis (204). However, prior to my work, an extracellular receptor for AMP was not believed to exist. Indeed, AMP was thought of as the sole silent intermediate in an extracellular hydrolysis pathway in which both the upstream (ATP and ADP, which activate P2X and P2Y receptors) and downstream elements (adenosine, which activates adenosine receptors) had active signaling roles (75). The fact that AMP activates the A$_1$ receptor independent of hydrolysis to adenosine, considering the biological ubiquity of AMP, necessitates a fundamental reevaluation of A$_1$R-mediated signaling.

For example, one area in which AMP activity through the A$_1$ receptor may be important is in the regulation of sleep and hibernation. Circulating AMP concentration varies in a circadian fashion and is elevated in mice exposed to continuous darkness (82). Intraperitoneal injection of AMP also induces a hypothermic state similar to torpor, although there is some disagreement as to whether this state reflects true torpor (205). Strikingly, intraventricular injection of a selective A$_1$R agonist induces torpor and injection of an A$_1$R antagonist reverses spontaneous torpor in the arctic ground squirrel, a hibernating mammal (206). Furthermore, central administration of a selective A$_1$R agonist induces a similar
torpor-like state in rats (127), a non-hibernating mammal. These studies indicate that both circulating AMP levels and A1R activity in the CNS are very important in mediating hypothermic metabolic states during torpor or hibernation. Thus, it is possible that AMP signaling through A1R may play a role in this metabolic regulation.

Clearly, future studies are needed to delineate the biological functions of AMP and adenosine signaling through the A1 receptor. However, there is reason to believe that such studies may be very difficult to perform. In vivo signaling environments are significantly more complex than the highly controlled systems used to evaluate adenosine receptor signaling in Chapter 2. Multiple, redundant enzymes which hydrolyze AMP to adenosine exist in vivo, including three (PAP, NT5E, and tissue-nonspecific alkaline phosphatase) in the dorsal root ganglia alone (207), which will hamper the use of genetic approaches. Likewise, a lack of known inhibitors for all such enzymes, as well as bioavailability/delivery concerns will limit the effectiveness of pharmacological inhibition strategies. Thus, even using a combination of genetic and pharmacological approaches the complete elimination of AMP hydrolysis in a biologically relevant setting may prove to be an impossible task. Indeed, due to the ubiquity of both AMP and adenosine, even accurately evaluating the degree to which enzymatic hydrolysis of AMP has been abolished would be very difficult. Furthermore, extracellular adenosine is primarily generated via AMP hydrolysis (75), and also activates A2A, A2B and A3 receptors, so even with the complete elimination of extracellular AMP hydrolysis, changes in A2AR-, A2BR-, and A3R-mediated signaling due to decreases in adenosine would complicate the analysis of A1R signaling.

Nevertheless, clever experimental design may allow the biological signaling roles of adenosine and AMP to be teased apart. For example, one promising experiment entails the
creation of a knockin mouse expressing an AMP-insensitive A₁ receptor in place of wild-type A₁R. Specifically, this mouse would express a receptor in which the residue homologous to histidine 251 is mutated to alanine, as in Figure 2.11. Despite the A₁ receptor’s ubiquitous expression and importance in regulation of the cardiovascular system, A₁R knockout mice are completely viable and have been used for various behavioral studies (70,76,108,109). Thus, it is likely that a knockin mouse expressing a mutated A₁ receptor would survive as well. The A₁ receptors expressed by this mouse should be resistant to activation by AMP, but should retain wild-type sensitivity towards adenosine (Fig. 2.11). Therefore, these mice should exhibit a systemic lack of extracellular AMP signaling, but unaffected adenosine signaling. Phenotypic analysis of these mice – evaluation of sleep behavior/circadian rhythms, cardiovascular function, or nociceptive behavior, for example – and comparison to wild-type mice should lead to a better understanding of the biological roles of AMP signaling through the A₁ receptor.

During my graduate work, I also discovered that AMP preferentially activates Gαᵢ over Gαᵣ through A₁R (Fig. 2.6, Fig. 3.2), one of the first known instances of functional selectivity by an endogenous signaling molecule. Functional selectivity has been heavily studied in recent years, with a particular focus on the potential of functionally selective compounds in drug design (35,119). Nevertheless, very little work has been done to examine functional selectivity in the context of endogenous signaling. The physiological trace amine N,N-dimethyltryptamine (DMT) stimulates calcium mobilization downstream of the 5-HT₂A serotonin receptor with an efficacy approximately 25% of that of serotonin itself (208). However, this may not be functional selectivity per se, as the efficacies of serotonin and DMT at 5-HT₂AR have not been compared via other downstream signaling pathways (i.e.
DMT could simply be a universally low-efficacy agonist). Furthermore, DMT is only present in vivo in very small amounts, so the biological relevance of this activity is suspect. Additionally, discrepancies in the efficacy of the endogenous cannabinoid receptor agonist anandamide have been observed by different groups when measuring different downstream signaling pathways (209), but these differences have not been rigorously confirmed in a single laboratory. In contrast to these studies, AMP is known to be present in vivo in significant quantities (with concentrations regulated by light exposure and food consumption), and the differential efficacy of AMP was measured in two very similar signaling assays under identical conditions. These results suggest that functional selectivity may have an important role in endogenous GPCR signaling.

A confounding problem in the investigation of the endogenous role of GPCR functional selectivity is the limited number of GPCRs that are known to have more than one physiological ligand. This complicates the analysis of functional selectivity by preventing comparisons between endogenous ligands, thus necessitating the use of synthetic ligands to define ‘full agonist’ activity (which may or may not be accurate, particularly if only a few synthetic agonists have been developed for a given receptor). For example, the 5-HT$_{1A}$, 5-HT$_{2A}$, and 5-HT$_{2C}$ serotonin receptors are activated by both serotonin and DMT, a closely related compound (210,211). However, as mentioned above, DMT is present at very low levels in most biological systems and thus has little relevance as an endogenous signaling molecule. Additionally, some P2Y receptors (notably P2Y$_2$) are sensitive to both adenine and uridine nucleotides (212), and the CB$_1$ and CB$_2$ cannabinoid receptors are activated by multiple endocannabinoid ligands, including anandamide and 2-arachidonoyl glycerol (213).
Lastly, the metabotropic glutamate receptor mGluR4 is sensitive to the protein metabolite phosphoserine as well as glutamate (214).

Nevertheless, the vast majority of GPCRs are either orphan receptors with no known ligand, or have exactly one known endogenous ligand. To a great extent, the lack of known receptors with multiple biological ligands is simply due to a lack of investigation. Despite the existence of many ligands which activate multiple receptors, it is largely assumed that each receptor is activated by a single ligand. By this logic, if one biological ligand has been identified for a given receptor, there is no need to search for others. Indeed, I assumed that this was true regarding the A1 receptor, until my serendipitous discovery that a second ligand did indeed exist.

High-throughput screening to identify ligands of orphan GPCRs has now been taking place for nearly two decades (215,216). My discovery of a second endogenous A1R ligand, together with the studies discussed above, suggest that these screening efforts should be expanded considerably. Notably, all of the agonist pairs (or families, in the case of the endocannabinoids) identified thus far that activate a single GPCR are chemically very similar, suggesting that the most profitable way to search for additional GPCR ligands is among biological compounds closely related to the known ligand. Thus, any such structurally related candidate molecules should also be screened against GPCRs with known endogenous ligands, as part of or in addition to current orphan GPCR screening efforts. Furthermore, for the growing number of GPCRs at which multiple endogenous ligands have been identified, the functional selectivity of each ligand should be systematically evaluated using assays which measure as many downstream signaling pathways as possible.
GPCRs are an absolutely fundamental part of eukaryotic cellular signaling. Indeed, it is hard to overstate their importance in modern drug discovery and pharmacology: over 30% of currently marketed small-molecule drugs target GPCRs (2). However, that is not to say that GPCR pharmacology is without its challenges. Biological regulation of GPCR-activating ligands is incredibly complex, and blanket stimulation or inhibition of GPCRs in vivo often has undesirable effects by interfering with endogenous signaling patterns. This is especially true of GPCRs whose endogenous ligands are critical neurotransmitters or signaling molecules. For example, serotonin receptor agonists have psychedelic effects and are of limited medical use, whereas serotonin reuptake inhibitors – which enhance available levels of serotonin after endogenous release, but have no activity at serotonin receptors themselves – have immense therapeutic value as antidepressants. This problem can largely be addressed by drugs that do not activate or inhibit GPCRs, but adjust the signaling caused by endogenous ligands; that is to say, GPCR modulators.

One possibility is the development of drugs that directly modulate GPCR signaling by binding to a secondary (allosteric) binding site on the receptor. Allosteric modulator binding alters receptor conformation in such a way that does not cause downstream signaling alone, but affects (either positively or negatively) the degree of downstream signaling that occurs when the receptor is activated by a true agonist. The most well-known example of a drug class that has this mechanism is the anxiolytic/sedative benzodiazepines, which function as positive allosteric modulators of the GABA<sub>A</sub> receptor (217). The phenomenon is also very important in physiological signaling, as the inhibitory neurotransmitter glycine is also a positive allosteric modulator of NMDA-type glutamate receptors (218). However, most of the work on allosteric modulators thus far has focused on ion channels (219), although there
have been recent advances in the development of allosteric GPCR modulators (220). Notably, many ion channels have large extracellular domains with a great deal of exposed surface area, and altering ion channel pore size offers a simple mechanism for signal modulation. Conversely, the vast majority of GPCRs (all except the small class C subfamily) have very small extracellular domains (221) and the nature of the conformational changes that would have the desired modulatory effects is very poorly understood, which may limit the development of allosteric GPCR modulators.

Thus, there is also great promise in targeting other proteins which regulate GPCR signaling for drug discovery. As with direct GPCR modulators, this strategy may avoid the side effects that accompany direct activation or inhibition of GPCRs. Furthermore, this strategy would allow for the modulation of multiple GPCRs simultaneously. It is recognized that nonselective GPCR-targeting drugs (both agonists and antagonists) have been significantly more effective in the clinic than highly selective ones, particularly for psychological indications (222). These drugs have been dubbed ‘magic shotguns’ (as opposed to more selective ‘magic bullets’), and drugs targeting GPCR modulators should benefit from a similar breadth of function. Indeed, the receptor selectivity of drugs targeting GPCR modulators should be determined more by the tissue and cellular distribution of the modulators themselves, and not by GPCR family or structural similarity. This may aid in the treatment of diseases in which dysregulated GPCR signaling is localized to a particular target tissue, but is not limited to a single receptor.

Fortunately for such drug discovery efforts, there are multiple protein families which are critical in the regulation of GPCRs, including most notably the G protein-coupled receptor kinase (GRK) family (223) and the arrestin family (224). The regulator of G protein
signaling (RGS) family is also important in the regulation of GPCR signaling, although RGS proteins do not modulate GPCRs themselves. Instead, they enhance the GTPase activity of the associated Ga subunits, attenuating G protein signaling after GPCR activation (225). My graduate work has added DGKη, a seemingly unrelated lipid kinase, to this list of GPCR-modulating enzymes, and other DGK isoforms may have similar activity. Indeed, drug discovery targeting members of any or all of these protein families may prove fruitful in the future. However, arrestins and RGS proteins act solely via protein-protein interactions, and do not possess enzymatic activity. This necessitates the development of protein-protein interaction inhibitors in order to affect arrestin or RGS function, which will make the discovery of effective compounds more difficult. Thus, the catalytically active GRK and DGK families are likely to provide more attractive targets, particularly using current ligand discovery strategies.

More specifically, since DGKη catalytic activity positively modulates GPCR signaling (Fig. 4.2), DGKη inhibitors may have therapeutic potential, particularly for the treatment of bipolar disorder, where increased DGKη expression is already implicated (142). However, pharmacological inhibition of DGKη may selectively affect only certain DGKη-mediated signaling pathways. DGKη is a very large protein with multiple and varied interaction domains (PH, C1, coiled-coil, and SAM), and DGKη enhances ERK signaling downstream of EGFR activation via a scaffolding mechanism unrelated to catalytic activity (226). In fact, modulation of EGFR activity by DGKη may be important in lung cancer, as DGKη depletion (as distinct from inhibition) reduced the growth of lung cancer cells and improved the efficacy of an EGFR inhibitor (146). Pharmacological inhibition of DGKη will most likely only affect the catalytic activity of DGKη, and not affect its scaffolding.
functions. Thus, therapeutic DGKη inhibitors will be better suited towards pathologies where the catalysis-dependant modulation of GPCR signaling is likely to be important (such as bipolar disorder), than diseases in which the catalysis-independent modulation of EGFR signaling is likely to be important (such as cancer).

Among protein families whose members regulate GPCR signaling, the DGK family is very diverse, containing ten unique isoforms with highly divergent expression profiles, some of which have multiple splicing variants (130). In contrast, the arrestin family contains only two non-visual isoforms, which are both widely expressed, and the GRK family contains five non-visual isoforms, three of which are widely expressed. Therefore, the DGK family may prove to be an exceptionally good target for the development of GPCR-regulating therapeutics, as the existence of so many isoforms with dramatically different expression profiles lessens the chance that a specific inhibitor of a single DGK isoform will either have broad systemic side effects due to global DGK inhibition, or will prove ineffective due to enzymatic compensation by other DGK isoforms in the target tissue. On the other hand, the existence of so many DGK isoforms may make the identification of a truly isoform-selective DGK inhibitor more difficult. Regardless, GPCR-modulating enzymes in general, and the DGK family in particular, constitute a target class with a great deal of untapped potential for drug discovery in the future.
REFERENCES


44. Feng, B., Li, Z., and Wang, J. B. Protein kinase C-mediated phosphorylation of the mu-opioid receptor and its effects on receptor signaling. *Mol Pharmacol* **79**, 768-775


kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. *Biochemistry* **31**, 3193-3197


138


of adenosine A(2A) receptor agonists activated by ecto-5'-nucleotidase. *J Med Chem* **52**, 7669-7677


127. Tupone, D., Madden, C. J., and Morrison, S. F. Central Activation of the A1 Adenosine Receptor (A1AR) Induces a Hypothermic, Torpor-Like State in the Rat. *J Neurosci* 33, 14512-14525


association study on bipolar disorder in the Bulgarian population. *Genes Brain Behav* **10**, 789-797


185. Dickson, E. J., Falkenburger, B. H., and Hille, B. Quantitative properties and receptor reserve of the IP(3) and calcium branch of G(q)-coupled receptor signaling. *J Gen Physiol* **141**, 521-535


